National Institute of Neurological Disorders and Stroke



Alzheimer's Disease-Related Dementias Summit 2025

April 29-30 & June 2, 2025

PROGRAM MATERIALS

Hosted by the National Institute of Neurological Disorders and Stroke
in partnership with: National Institute on Aging

Welcome Message from Dr. Walter J. Koroshetz

I am pleased to welcome you, virtually, to the "Alzheimer's Disease-Related Dementias (ADRD) Summit 2025." Together with the National Institute on Aging's Summits on Alzheimer's Disease Research and Care, Services, & Supports for Persons with Dementia and their Care Partners/Caregivers, the ADRD Summit responds to the National Alzheimer's Project Act (NAPA) signed into law in 2011. As with previous summits, the goal of the ADRD Summit 2025 is to solicit input from experts with deep expertise in a host of relevant science and disease-related areas. These committee members are asked to develop prioritized recommendations to guide scientific research during the next 5 to 10 years. In addition, the Summit will report progress on the research recommendations set by the 2022 ADRD Summit and will revise those recommendations based on scientific advances over the last 3 three years.

The group assembled will primarily focus on frontotemporal degeneration, Lewy body dementias, dementia with mixed/multiple etiologies, and vascular contributions to cognitive impairment and dementia. We are also interested in defining key research priorities to improve Alzheimer's Disease and related dementias outcomes for all people, including those at highest risk for AD/ADRD, and special scientific topics related to mixed etiology dementias, including TDP-43 pathology and post-TBI AD/ADRD.

On behalf of the National Institute of Neurological Disorders and Stroke (NINDS), I'd like to thank the many people who helped to make the Summit possible, including Kate Possin, the Scientific Chair, and the Session Chairs: Cynthia Carlsson, Kristen Dams-O'Connor, Kacie Deters, Silvia Fossati, James Galvin, Maria Glymour, Costantino Iadecola, David Irwin, Celeste Karch, Jonathan Kipnis, Hanzhang Lu, Farah Lubin, Kathleen Poston, and David Wolk. I also want to thank the leadership and staff of the National Institute on Aging, whose assistance has been invaluable, as well as others who helped support this event.

We appreciate your active participation in the Summit, which will include many opportunities for public questions and comments. Although a virtual format is unavoidable, we hope that this will increase participation and generate input from all corners of society impacted by dementia. With your input, we hope to make a significant contribution to the National Plan's goal to prevent and effectively treat Alzheimer's disease and Alzheimer's disease-related dementias.

Walter J. Koroshetz, M.D.
National Institute of Neurological Disorders and Stroke (NINDS) Director
National Institutes of Health

NIH National Institute of Neurological Disorders and Stroke

Table of Contents

Agenda

1. ADRD Summit 2025

Day 1 – Tuesday, April 29, 2025

11:00 a.m. EDT Welcome Remarks and Introduction

Walter Koroshetz, M.D.
Director, NINDS, NIH

Progress and Updating Research Recommendations for the Alzheimer's Disease-Related Dementias

Amber McCartney, Ph.D.
NINDS, NIH

Kate Possin, Ph.D., Scientific Chair
University of California, San Francisco

11:45 a.m. SESSION 1: Multiple Etiology Dementias (MED) – Research for Implementation of Discoveries into Practice

Session Chair:
Kate Possin, Ph.D.
University of California, San Francisco

Introduction, Enhancing Collaborative Care Models

Kate Possin, Ph.D.
University of California, San Francisco

Linking Detection and Diagnosis with Quality Care

Julie Wood, M.D.
American Academy of Family Physicians (AAFP)

Improving Access to Care and Research

Jennifer Hagerty Lingler, Ph.D.
University of Pittsburgh, School of Nursing

Evaluating Interventions to Improve Brain Health and Mitigate Cognitive Decline

Heather Snyder, Ph.D.
Alzheimer's Association

12:15 p.m. **SESSION 1: Public Comment and Panel Discussion**

Panelists: *Katherine Possin, Ph.D., Jeff Burns, M.D., Cynthia Carlsson, M.D., Hyun Joo (Sophie) Cho, M.D., Josh Chodosh, M.D., Lenise Cummings-Vaughn, M.D., Nicole Fowler, Ph.D., Rebecca Hommer, M.D., Lee Jennings, M.D., Jason Karlawish, M.D., Ian Kremer, J.D., Shari Ling, M.D., Jennifer Hagerty Lingler, Ph.D., Joelle Millikin, M.D., Huong Nguyen, Ph.D., RN, Ozioma Okonkwo, Ph.D., Christine Ritchie, M.D., Heather Snyder, Ph.D., Michael Wolf, Ph.D., Julie Wood, M.D.*

12:30 p.m. **Lunch Break**

1:00 p.m. **Perspective: The Patient Behind the Priorities**

Linde Jacobs, RN

1:10 p.m. **SESSION 2: Frontotemporal Dementias (FTD)**

Session Co-Chairs:
Celeste Karch, Ph.D.
Washington University in St. Louis

David Irwin, M.D.
University of Pennsylvania

Introduction

Celeste Karch, Ph.D.
Washington University in St. Louis

FTD Clinical Trials and Epidemiology

Adam Boxer, M.D., Ph.D.
University of California, San Francisco

Advancing FTD Biomarkers to Disentangle FTD Clinicopathological Heterogeneity

David Irwin, M.D.
University of Pennsylvania

Developing and Validating FTD Research Models

Celeste Karch, Ph.D.
Washington University in St. Louis

Understanding FTD Disease Mechanisms to Identify Potential Therapeutic Targets

Aimee Kao, M.D., Ph.D.
University of California, San Francisco

Identifying Genetic and Molecular Modifiers of FTD Risk and Resilience and Accelerating Therapeutic Discovery

Bess Frost, Ph.D.
Brown University

1:55 p.m. **SESSION 2: Public Comment and Panel Discussion**

***Panelists**: David Irwin, M.D., Celeste Karch, Ph.D., Sami Barmada, M.D., Ph.D., Nicole Bjorklund, Ph.D., Adam Boxer, M.D., Ph.D., Kristophe Diaz, Ph.D., Bess Frost, Ph.D., Aaron Gitler, Ph.D., Danielle Graham, Ph.D., Linde Jacobs, RN, Aimee Kao, M.D., Ph.D., Cristian Lasagna-Reeves, Ph.D., Lisa Opanashuk, Ph.D., Alessandra Rovescalli, Ph.D., Frank Shewmaker, Ph.D., Carmela Tartaglia, M.D., Michael Ward, M.D., Ph.D.*

2:10 p.m. **Break**

2:20 p.m. **SESSION 3: MED – Post Traumatic Brain Injury (TBI) AD/ADRD**

Session Chair:
Kristen Dams-O'Connor, Ph.D.
Icahn School of Medicine at Mt. Sinai

Introduction to Post-TBI AD/ADRD, Longitudinal Multimodal Study of Heterogeneous Post-TBI AD/ADRD Phenotypes and Clinicopathological Relationships

Kristen Dams-O'Connor, Ph.D.
Icahn School of Medicine at Mt. Sinai

Interdisciplinary Collaboration and Data Sharing Among TBI and Dementia Researchers to Advance TBI-AD/ADRD Science

Neil Graham, Ph.D.
Imperial College of London

Basic and Translational Research to Identify Mechanistic Pathways and Elucidate Therapeutic Targets for Post-TBI AD/ADRDs

Andre Obenaus, Ph.D.
University of California, Riverside

Accelerating Translation for Clinical Application and Knowledge Sharing with People Living with TBI and/or Post-TBI AD/ADRD

Monique Pappadis, Ph.D.
University of Texas, Medical Branch

2:50 p.m. **SESSION 3: Public Comment and Panel Discussion**

***Panelists**: Kristen Dams-O'Connor, Ph.D., Regina Armstrong, Ph.D., Hibah Awwad, Ph.D., Joe Bonner, Ph.D., Bernadette D'Alonzo, Ph.D., Brian Edlow, M.D., Sarah Fontaine, Ph.D., Neil Graham, Ph.D., David Gutman, M.D., Ph.D., Scott Hamilton, Stuart Hoffman, Ph.D., Victoria Johnson, Ph.D., Dirk Keene, M.D., Ph.D., Edward Lee, M.D., Ph.D., Ann McKee, M.D., Andre Obenaus, Ph.D., Lisa Opanashuk, Ph.D., Monique Pappadis, Ph.D., Mary Jo Pugh, Ph.D., RN, Heather Snyder, Ph.D., George Sopko, M.D., Rob Turner II, Ph.D., Nsini Umoh, Ph.D., Keenan Walker, Ph.D.*

3:05 p.m. **Break**

3:15 p.m. **SESSION 4: MED – LATE (TDP-43 in Common Late-Onset Dementias)**

Session Chair:
David Wolk, M.D.
University of Pennsylvania

Introduction, Gaps and Opportunities for a Deeper Characterization of LATE/LATE-NC

Hyun-Sik Yang, M.D.
Brigham and Women's Hospital & Harvard Medical School

In-vivo Markers and Clinical Criteria for LATE/LATE-NC

Konstantinos Arfanakis, Ph.D.
Rush University Medical Center

Finding the Causes of LATE-NC and Therapeutic Opportunities

Nicolas Fawzi, Ph.D.
Brown University

Hippocampal Sclerosis of Aging, a Common Comorbidity with LATE-NC: Opportunities and Challenges

Peter Nelson, M.D., Ph.D.
University of Kentucky

3:45 p.m. **SESSION 4: Public Comment and Panel Discussion, Panelists**

***Panelists**: David Wolk, M.D., Konstantinos Arfanakis, Ph.D., Selen Catania, Ph.D., Penny Dacks, Ph.D., Nicolas Fawzi, Ph.D., Tamar Gefen, Ph.D., Claudia Kawas, M.D., Tong Li, Ph.D., Linda McGavern, Ph.D., Peter Nelson, M.D., Ph.D., Leonard Petrucelli, Ph.D., Rosa Rademakers, Ph.D., Deidre Robokos, Anja Schneider, M.D., Julie Schneider, M.D., Nina Silverberg, Ph.D., Philip Wong, Ph.D., Hyun-Sik Yang, M.D., Paul Yushkevich, Ph.D.*

4:00 p.m. **Adjourn Day 1**

Day 2 – Wednesday, April 30, 2025

11:00 a.m. EDT Welcome Remarks

Walter Koroshetz, M.D.
Director, NINDS, NIH

Kate Possin, Ph.D.
University of California, San Francisco

11:05 a.m. Perspective: Preventing and Treating Dementia: Research Priorities to Accelerate Progress (National Academies of Sciences, Engineering, and Medicine Report)

Nilüfer Ertekin Taner, M.D., Ph.D.
Mayo Clinic

11:20 a.m. Questions and Answers

11:25 a.m. SESSION 5: MED – Basic and Clinical Discovery Research

Session Co-Chairs:
Cynthia Carlsson, M.D.
University of Wisconsin-Madison

Constantino Iadecola, M.D.
Weill Cornell Medical College

Introduction, MED Clinical Research, Biosamples and Biomarkers

Cynthia Carlsson, M.D.
University of Wisconsin-Madison

MED Basic and Translational Research

Costantino Iadecola, M.D.
Weill Cornell Medical College

MED Data Harmonization, Standardization and Integration

David Fardo, Ph.D.
University of Kentucky

MED Workforce Development

Caitlin Latimer, M.D., Ph.D.
University of Washington

11:55 a.m. **SESSION 5: Public Comment and Panel Discussion**

Panelists: *Cynthia Carlsson, M.D., Costantino Iadecola, M.D., Diane Bovenkamp, Ph.D., Ana Maria Cuervo, M.D., Ph.D., Dave Fardo, Ph.D., Rebecca Gottesman, M.D., Ph.D., Rebecca Hommer, M.D., Yadong Huang, M.D., Ph.D., Bistra Iordanova, Ph.D., Greg Jicha, M.D., Ph.D., Caitlin Latimer, M.D., Ph.D., Linda McGavern, Ph.D., Jason Meyer, Ph.D., Gil Rabinovici, M.D., Laura Ranum, Ph.D., Nina Silverberg, Ph.D., Meg Smith, J.D., Larry and Karen Squiers, Keith Vossel, M.D.*

12:10 p.m. **Lunch Break**

12:40 p.m. **SESSION 6: Lewy Body Dementias (LBD)**

Session Co-Chairs:
James Galvin, M.D.
Miami University

Kathleen Poston, M.D.
Stanford University

Introduction

James Galvin, M.D.
Miami University

LBD Clinical Trials and Cohorts

Juan Toledo Atucha, M.D.
Houston Methodist Hospital

Biomarkers for Diagnosis and Progression of LBD

Elizabeth Mormino, M.D.
Stanford University

Genomics and Multi-Omics, and Neuropathology in LBD

Brittany Dugger, Ph.D.
University of California, Davis

LBD Mechanisms and Basic Science

Alice Chen-Plotkin, M.D.
University of Pennsylvania

1:25 p.m. **SESSION 6. Public Comment and Panel Discussion**

Panelists: *James E. Galvin, M.D., Kathleen Poston, M.D., John Alam, M.D., Juan Toledo Atucha, M.D., Debra Babcock, Ph.D., Bradley Boeve,*

M.D., Alice Chen-Plotkin, M.D., Brittany Dugger, Ph.D., Douglas Galasko, M.D., Laurence Guttmacher, M.D., Elizabeth Mormino, M.D., Sonja Scholz, Ph.D., John-Paul Taylor, Ph.D., Angela Taylor

1:40 p.m. **Break**

1:45 p.m. **SESSION 7: Vascular Contributions to Cognitive Impairment and Dementia (VCID)**

Session Co-Chairs:
Silvia Fossati, Ph.D.
Temple University

Hanzhang Lu, Ph.D.
Johns Hopkins University

Introduction, VCID Basic Mechanisms

Silvia Fossati, Ph.D.
Temple University

VCID Translational Research

Gareth Howell, Ph.D.
The Jackson Laboratory

VCID Human Studies

Sudha Seshadri, M.D.
UT Health, San Antonio

VCID Biomarkers

Hanzhang Lu, Ph.D.
Johns Hopkins University

2:30 p.m. **SESSION 7: Public Comment and Panel Discussion**

***Panelists**: Silvia Fossati, Ph.D., Hanzhang Lu, Ph.D., Candice Brown, Ph.D., Susan Catalano, Ph.D., Jue Chen, Ph.D., Roderick Corriveau, Ph.D., Crystal Glover, Ph.D., Rebecca Gottesman, M.D., Ph.D., Gareth Howell, Ph.D., Costantino Iadecola, M.D., David Kleinfeld, Ph.D., David Knopman, M.D., Jin-Moo Lee, M.D., Ph.D., Anne Leonard, RN, Elizabeth Newman, Ph.D., Yakeel Quiroz, Ph.D., Natalia Rost, M.D., Julie Schneider, M.D., Azizi Seixas, Ph.D., Sudha Seshadri, M.D., Heather Snyder, Ph.D., Farzaneh Sorond, M.D., Ph.D., Andrew Yang, Ph.D., Xiling Yin, M.D., Ph.D., Kristen Zuloaga, Ph.D.*

2:45 p.m. **Break**

2:50 p.m. **Further Public Comment and Panel Discussion**

Kate Possin, Ph.D., Moderator
University of California, San Francisco

3:45 p.m. **Scientific Chair's Highlights and Cross-Cutting Themes**

Kate Possin, Ph.D.
University of California, San Francisco

4:00 p.m. **Adjourn Day 2**

Day 3 – Monday, June 2, 2025

1:00 p.m. EDT **Welcome**

Walter Koroshetz, M.D.
Director, NINDS, NIH

Kate Possin, Ph.D.
University of California, San Francisco

1:10 p.m. **SESSION 8: Research to Improve Outcomes for Representative Populations at Risk and Living with AD/ADRD**

Session Co-Chairs:

Maria Glymour, Ph.D.
Boston University

Kacie Deters, Ph.D.
University of California, Los Angeles

Introduction

Maria Glymour, Ph.D.
Boston University

Research Infrastructure for Advancing Prevention and Care

Kacie Deters, Ph.D.
University of California, Los Angeles

Workforce

Miguel Arce-Renteria, Ph.D.
Columbia University

Assessment, Treatment, and Care

Carl Hill, Ph.D.
Alzheimer's Association

Prevention

Indira Turney, Ph.D.
NIH/NIA/Intramural Research Program

Monitoring Progress

Elizabeth Rose Mayeda, Ph.D.
University of California, Los Angeles

1:55 p.m. **Session 8: Public Comment and Panel Discussion**

***Panelists**: Maria Glymour, Ph.D., Kacie Deters, Ph.D., Richard Benson, M.D., Ph.D., Marishka Brown, Ph.D., Sara Dodson, Ph.D., Paola Gilsanz, ScD, Carl Hill, Ph.D., Timothy Hohman, Ph.D., Rebecca Hommer, M.D., Virginia Howard, Ph.D., Damali Martin, Ph.D., Elizabeth Rose Mayeda, Ph.D., Miguel Arce-Renteria, Ph.D., Ralph and Mollie Richards, Jacqueline Torres, Ph.D., Indira Turney, Ph.D., Charles Windon, M.D., Charisse Winston, Ph.D., Michael Wolf, Ph.D.*

2:10 p.m. **Break**

2:20 p.m. **SESSION 9: MED – Impact of Exposome on AD/ADRD Risk & Outcomes**

Session Co-Chairs:
Farah Lubin, Ph.D.
University of Alabama at Birmingham

Jonathan Kipnis, Ph.D.
Washington University in St. Louis

Introduction and Exploring Exposome-Body Interactions: Microbial and Infectious Influences on AD/ADRD Risk, Progression, and MED

Farah Lubin, Ph.D.
University of Alabama at Birmingham

Insights into Exposome-Driven Pathogenic Mechanisms in AD/ADRD Neuropathology

Melissa Lamar, Ph.D.
Rush University Medical Center

Building Research Frameworks: Investigating Exposome Impact on AD/ADRD Risk, Outcomes, and Neurocognitive Impairments

Aisha Dickerson, Ph.D.
Johns Hopkins University

Developing Therapeutics and Countermeasures: Exposome-Driven Interventions for AD/ADRD at Individual and Community Levels

Meg Smith, J.D., CEO
Cure Alzheimer's Fund

2:50 p.m. **Session 9: Public Comment and Panel Discussion**

***Panelists**: Jonathan Kipnis, Ph.D., Farah Lubin, Ph.D., Staci Bilbo, Ph.D., William Daley, Ph.D., Neel Dhruv, Ph.D., Aisha Dickerson, Ph.D., Joseph Thomas Flies-Away, J.D., David Gate, Ph.D., David Holtzman, M.D., David*

Jett, Ph.D., Melissa Lamar, Ph.D., Vijay Limaye, Ph.D., Xiao-Hong Lu, Ph.D., Amy Nelson, Ph.D., Meg Smith, J.D.

3:05 p.m. **Further Public Comment and Panel Discussion**

Kate Possin, Ph.D., Moderator
University of California, San Francisco

3:45 p.m. **Scientific Chair's Highlights and Cross-Cutting Themes**

Kate Possin, Ph.D.
University of California, San Francisco

4:00 p.m. **Adjourn Day 3**

Biographies

1. Scientific Chair, ADRD Summit 2025 – Katherine Possin, Ph.D.

Katherine Possin, Ph.D.
University of California, San Francisco

Dr. Possin's research program focuses on improving the detection, diagnosis and care for people with neurodegenerative disease from diverse backgrounds and settings. She is the director of the DetectCID Consortium, focused on improving the detection of cognitive impairment in primary care. She is the project lead of TabCAT, a software platform for tablet-based cognitive testing frequently used in research studies and clinical services. The Brain Health Assessment is a 10-minute assessment on TabCAT designed to help primary care providers to detect and diagnose Alzheimer's and related disorders. She is the principal investigator of the Care Ecosystem, a telephone-based supportive care program for persons with dementia and their caregivers that improves quality of life for people living with dementia and their caregivers and reduces emergency-related care. Throughout her work, she is dedicated to reducing healthcare disparities related to dementia. She currently holds the John Douglas French Alzheimer's Foundation Endowed Professorship at the UCSF Memory and Aging Center, is faculty member at the Global Brain Health Institute, and is the UCSF ADRC Clinical Core Co-Director.

2. NAPA Council Chair for ADRD Summit 2025 – Adrienne Mims, M.D.

Adrienne Mims, M.D.
Rainmakers Solutions

Dr. Mims first started her college education at George Washington University, where she earned her undergraduate degree in Zoology in 1978. She then attended Stanford University School of Medicine, where she was involved in SNMA, and graduated with her medical degree in 1982. At the University of California, Los Angeles – School of Public Health, she received her MPH degree in Epidemiology in 1990. She completed a residency in Family Medicine at Martin Luther King Jr./ Charles Drew Medical Center in Los Angeles.

As the Chief of Prevention and Health Promotion, Dr. Mims served at Kaiser Permanente for 17 years. She then worked as the APS Healthcare Medical Director from 2007-2009, followed by a job at Alliant Health Solutions as the Medical Director – Medicare Quality Improvement, from 2009-2013. Dr. Mims then took on the Vice President, Chief Medical Officer role until 2020. She then started a job as a Geriatrician at JenCare Senior Medical Center in Morrow, GA.

Dr. Mims has long been involved with local and international medical associations. She was the President of the American Health Quality Association (AHQA) from 2013-2014, a Board Member and Chair of the Audit Committee with the American Geriatrics Society from 2009-2015, GAFP Delegate and Board Member from 2008-2018, and Vice-Chair Board of Directors for the PCPI Foundation 2015-2018. She is currently a Retirement Research Foundation Board of Trustees Member and a Board Member for the NCQA.

Dr. Mims has extensive clinical practice experience in value-based care for adults and seniors through her long tenure with Kaiser Permanente. She is the founding medical director at the Center for Black Women's Wellness – Safety Net Clinic, where she also worked as a Staff Physician for eight years. Dr. Mims was the founding medical director of the Georgia Medicaid Management Program, overseeing case and disease management services to 500,000 aged, blind, and disabled Medicaid recipients.

Dr. Mims currently works at Rainmakers Strategic Solutions LLC as the Chief Medical Officer. specializing in operations management, training and education, program management, data analytics, and stakeholder engagement for federal agencies. Dr. Mims focuses on leadership and the development and execution of key health care quality improvement initiatives. Her other contributions include writing several Patient Education FAQ forms, which were published in the Journal of the American Geriatric Society, and writing "Teaching the Older Adult, published by the Journal of the American Geriatric Society in 2005.

3. SESSION CHAIRS

Cynthia Carlsson, M.D., Session Co-Chair

University of Wisconsin-Madison

Dr. Carlsson is a Professor of Medicine and the Louis A. Holland, Sr., Professor in Alzheimer's Disease in the Division of Geriatrics at the University of Wisconsin-Madison School of Medicine and Public Health and the Madison Veterans Affairs Hospital. Dr. Carlsson's clinical research focuses on early detection and prevention of Alzheimer's disease, focusing on vascular risk factor modification and integrated use of neuroimaging, spinal fluid, blood, and cognitive biomarkers. She has received research grant support from NIH, the Department of Veterans Affairs, the University of Wisconsin, the Wisconsin Department of Health Services, and other philanthropic organizations and industry sponsors and has published over 150 research papers.

At the NIH-funded Wisconsin Alzheimer's Disease Research Center, Dr. Carlsson serves as Leader of the Clinical Core and Co-Leader of the Biomarker Core. As a physician trained in geriatric medicine, Dr. Carlsson has served as Co-Director of the Madison VA Memory Assessment Clinic since 2003 where she continues to see patients with cognitive concerns weekly. Dr. Carlsson has been a part of national initiatives to improve dementia research, clinical care, and services for older adults and currently serves as Chair for the US Health and Human Services Advisory Council on Alzheimer's Research, Care, and Services. In addition, she is involved with NIA and VA-led national dementia research and clinical care initiatives and serves on the Steering Committee for the Wisconsin State Dementia Plan. As Director of the UW-Madison Wisconsin Alzheimer's Institute, Dr. Carlsson oversees dementia clinical care education for practicing clinicians across the state.

Kristen Dams-O'Connor, Ph.D., Session Chair

Icahn School of Medicine at Mt. Sinai

Dr. Dams-O'Connor is Jack Nash Professor and Vice Chair of Research in the Department of Rehabilitation and Human Performance at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY. She serves as Director of the Brain Injury Research Center (BIRC) of Mount Sinai and is a Professor of Neurology at ISMMS. Her multidisciplinary research program aims to identify mechanisms, risk, and protective factors to improve long-term outcomes in individuals with traumatic brain injury (TBI) and repetitive head trauma sustained through sports participation, military service, and intimate partner violence. She leads the Late Effects of TBI (LETBI) Project, a TBI brain donor program focused on characterizing the clinical phenotype and postmortem

pathological signatures of post-traumatic neurodegeneration and associations with Alzheimer's disease (AD) and AD-related dementias (ADRDs).

Her team uses modern psychometric and statistical techniques to measure individual differences in trajectories of change over time among survivors of TBI. One goal of this work is to improve diagnosis of secondary post-traumatic conditions during life so they can be treated. She is Project Director of the New York Traumatic Brain Injury Model System of care, one of 16 centers of excellence for TBI research and clinical care in the United States. Her research is supported by federal grants from the National Institutes of Health, National Institute for Disability Independent Living and Rehabilitation Research, Department of Defense, Centers for Disease Control, and Patient Reported Outcomes Research Institute. She has published over 150 manuscripts and chapters on TBI treatments and outcomes and has presented her research internationally.

Kacie Deters, Ph.D., Session Co-Chair
University of California, Los Angeles

Dr. Kacie Deters earned her Bachelor's in Biology from the University of Alabama, Birmingham and her Master's in Biology from CSU Dominguez Hills. Science turned into a passion Kacie wanted to explore more. In 2017, she earned her Ph.D. in Medical Neuroscience at the Indiana University School of Medicine focusing on genetic and imaging characteristics of tauopathies, including Alzheimer's disease. During her postdoc at Stanford University with Dr. Elizabeth Mormino, she first began to explore ethnic and racial disparities in AD biomarkers. COVID hit, and Kacie decided to take a second postdoc, which she completed in 2022 at the University of California, San Diego while figuring out what career path she wanted to take. Ultimately, Kacie wanted to give back to the community and support minoritized scientists, and Kacie joined UCLA as faculty in July of 2022 where her research program focuses on health equity research for cognitive decline and Alzheimer's disease and related dementias in older adults, primarily from the Black community.



Silvia Fossati, Ph.D., Session Co-Chair
Temple University

Dr. Fossati earned an undergraduate degree in molecular biology, then went on to complete her Ph.D. at the University of Florence in pharmacology and toxicology. It was here that she got her first experience studying the brain, a part of the body that had always fascinated her. Her research focused on ischemia. Through this research, she began to see the connections to neurodegeneration. Looking back, she can see very similar pathways to Alzheimer's disease, her current research focus.

Dr. Fossati secured a two-year Postdoctoral Fellowship position at NYU, where she focused her work on Alzheimer's disease, vascular dementia, and amyloidosis. It was here that she earned her first research faculty position. It was also during her time at NYU that Dr. Fossati began receiving the first of her grants, including an Alzheimer's Association Young Investigator Grant and a Pilot Grant from the NYU Alzheimer's Center.

Seven years after arriving at NYU, Dr. Fossati became Assistant Professor in the Departments of Neurology and Psychiatry, studying molecular mechanisms and new therapeutic interventions in Alzheimer's disease and vascular amyloidosis, and collaborating with the Director of the Center of Cognitive Neurology, the Director of the Center for Brain Health, and the Chairman of Psychiatry in biomarker studies.

In 2019, Dr. Fossati took a position at Temple University. Her appointment coincided with the establishment of a new Alzheimer's Center at the university. Dr. Fossati's work at the Center focuses on the molecular pathogenesis of disorders of the brain and vascular system and cell-death mechanisms that cause neurodegeneration in Alzheimer's Disease, cerebral amyloid angiopathy, traumatic brain injury, and post-traumatic stress disorder.

As part of her research, she collaborates with other groups, organizations, and researchers, including the Alzheimer's disease Research Center and the Cohen Veterans Center, both at NYU.

James E. Galvin, M.D. MPH, Session Co-Chair
Miami University

Dr. James E. Galvin is the Founding Director of the Comprehensive Center for Brain Health and Professor of Neurology and Professor of Psychiatry and Behavioral Sciences at the University of Miami School of Medicine. He is a board-certified Neurologist and Chief of Cognitive Neurology Division. Previously, Dr. Galvin served on the Faculty at Hahnemann University, Washington University in St Louis, New York University, and Florida Atlantic University. He is Director and Principal Investigator of the Lewy Body Dementia Association Research Center of Excellence, one of 25 Centers in the United States.

He has been continuously funded by the National Institutes of Health for more than 20 years and has been awarded nearly 100 million dollars in Federal and State grants. He has published more than 275 peer-reviewed papers in top-tier scientific journals. Dr. Galvin's research focus is on the development of novel and innovative approaches to study brain health and the risk of cognitive impairment, holding 13 copyrights for instruments used across the world including the AD8, Quick Dementia Rating System (QDRS), and Lewy Body Composite Risk Score (LBCRS).

He leads a multidisciplinary team of physicians, scientists, nurses, social workers, and physical therapists to investigate clinical, cognitive, functional, and behavioral features of healthy brain aging and neurodegenerative disease and their relationship to novel biomarkers of brain pathology including structural, functional and diffusion MRI, amyloid and tau PET scans, blood biomarkers of Alzheimer's and Parkinson's disease, electrophysiology, and computer-based behavioral testing.

Of particular interest to Dr Galvin and his team is the impact of sex, race, ethnicity, socioeconomic status, and geographic locale on brain health and the risk of future cognitive and functional impairment. His research has been funded by the National Institutes of Health, Centers for Disease Control, Alzheimer's Association, American Federation for Aging Research, Michael J Fox Foundation, Association for Frontotemporal Degeneration, Lewy Body Dementia Association, the Departments of Health of Florida, New York and Missouri, and numerous private and family foundations.

Maria Glymour, Ph.D., Session Co-Chair
Boston University

Upon completing her Master's and Doctoral degree, Glymour became a Robert Wood Johnson Foundation Health & Society Scholar in Social Epidemiology and subsequently joined the faculty at Harvard University. Her primary research interests focus on "how social factors experienced across the lifecourse, such as educational attainment and work environment, influence cognitive function, memory loss, stroke and other health outcomes in old age.

As a professor of Epidemiology and Biostatistics at the University of California, San Francisco, Glymour led the Ph.D. program in Epidemiology and Translational Science. She continued to conduct research on lifecourse social factors and late life health. Work with colleagues concluded that the longer a child remains in school, the higher their reduced risk for heart disease and improvements in several cardiovascular risk factors in adulthood becomes. During the COVID-19 pandemic in North America, Glymour collaborated on a study which found that California's lockdown suppressed excess COVID-19 related deaths.

Costantino Iadecola, M.D., Session Co-Chair
Weill Cornell Medical College

Costantino Iadecola, M.D. is the Director and Chair of the Feil Family Brain and Mind Research Institute and the Anne Parrish Titzell Professor of Neurology at Weill Cornell Medicine. His research focuses on the basic mechanisms of neurovascular function and on the cellular and molecular alterations underlying ischemic brain injury, neurodegeneration and other conditions associated with cognitive impairment.

A pioneer in establishing the concept of neurovascular unit, Dr. Iadecola has championed the involvement of neurovascular dysfunction in neurodegenerative diseases, and the role of innate immunity and the microbiome in ischemic brain injury. He has published over 390 papers in peer-reviewed journals and plays a leadership role in research organizations and funding agencies in the US and abroad. He has been involved, as editor or editorial board member, in several journals including Circulation research, Stroke, Hypertension, the Journal of Neuroscience, and the Annals of Neurology. Dr. Iadecola has received the McHenry Award from the American Academy of Neurology, two Jacob Javits Awards from the National Institutes of Health, the Willis Award-the highest honor in stroke research bestowed by the American Heart Association (AHA), the Zenith Fellow Award from the Alzheimer's Association, the Excellence Award in Hypertension Research (Novartis) from the Hypertension Council of the AHA, and the Chancellor's Award in Neuroscience from Louisiana State University. In

2015, he was elected to the Association of American Physicians. In 2019 Dr. Iadecola was selected Distinguished Scientist by the AHA and in 2021 he received the Basic Science Prize from the AHA. Clarivate Analytics lists Dr. Iadecola as one of world's "Highly Cited Researchers" for ranking in the top one percent of the most-cited authors in the field of neuroscience and behavioral sciences.

David Irwin, M.D., Session Co-Chair
University of Pennsylvania Perelman School of Medicine

Dr. Irwin is a cognitive neurologist, clinical core leader at the Penn FTDC, co-PI of the Lewy Body Dementia Association Research Center of Excellence at Penn, and PI of the Penn Digital Neuropathology Laboratory. He previously trained as a postdoctoral fellow at both the Penn FTDC under Dr. Murray Grossman and the Penn Center for Neurodegenerative Disease research under Dr. John Trojanowski where he had dual training in cognitive neurology and neuropathology/biomarkers in neurodegenerative disease. This blend of experiences in cognitive neurology and neuropathology led to the unique translational approach of the Penn DNPL. Dr. Irwin continues to evaluate and treat patients at the Penn FTDC. Dr. Irwin enjoys time with his wife and two small children who have taught him birding and gardening. He also enjoys fishing at the Schuylkill River each spring.

Celeste Karch, Ph.D., Session Co-Chair
Washington University in St. Louis

Dr. Karch is an Associate Professor of Psychiatry and leads the Biomarker Core in the Knight Alzheimer Disease Research Center at Washington University in St Louis. Dr. Karch is the Scientific Director of the Dominantly Inherited Alzheimer Network and a Chan Zuckerberg Neurogenerative Challenge Network Investigator. Dr. Karch's lab focuses on dissecting the molecular drivers of neurodegenerative diseases such as Alzheimer disease and frontotemporal dementia by integrating human stem cell models with mouse models and human tissue. Dr. Karch has built a somatic and stem cell collection containing a series of deeply clinically characterized cell lines from individuals carrying genetic drivers of Alzheimer disease, frontotemporal dementia, amyotrophic lateral sclerosis (ALS) and Parkinson disease. Dr. Karch has made seminal contributions to neurodegenerative disease research: defining the critical stages of SOD1 aggregation in ALS mouse models; defining mechanisms of tau secretion; and identifying a number of novel AD risk genes and their putative function. She is the recipient of numerous awards including the Rainwater Prize for Innovative Early-Career Scientists.

Jonathan Kipnis, Ph.D., Session Co-Chair
Washington University in St. Louis

Dr. Kipnis received his undergraduate degree in biology at Tel Aviv University in Ramat Aviv, Israel in 1998, and his Master's in neurobiology at the Weizmann Institute of Science in Rehovot, Israel in 1999.

For his graduate training, Kipnis remained at the Weizmann Institute of Science. He first worked with Moshe Oren in cancer immunology, but was inspired by Michal Schwartz, to pursue a Ph.D. in neuroimmunology. He joined Schwartz's lab the year that they discovered the therapeutic benefit of T cells in spinal cord and brain injury, a pioneering finding that began the study of the protective roles of autoimmunity in CNS disease. This was the beginning of Kipnis' career exploring the connections between the brain and the immune system.

In the Schwartz Lab, Kipnis' work focused on T cell based autoimmune reactions in CNS injury and neurodegeneration. Kipnis elucidated the pleiotropic roles of regulatory T cells in CNS injury versus CNS homeostasis. By depleting naturally occurring regulatory T cells after CNS injury, he was able to improve neuronal survival in mice. However, by up-regulating effector autoimmune T cells through immunization with CNS antigen, he was able to improve recovery after CNS injury. These results showed that the immune system's intrinsic mechanisms to protect against autoimmunity might not be beneficial when insults demand autoimmune effector function for tissue maintenance.

Kipnis remained at the Weizmann for his postdoctoral training in Schwartz's lab. In this period, he and other members of the lab discovered that brain antigen specific T cells play a role in neurogenesis and cognitive functions, such as memory and spatial learning. This was one of the seminal findings showing that the immune system, through T cells, plays a role in cognition and brain homeostasis.

His lab studies interactions between the immune system and nervous system. He is best known for his lab's discovery of meningeal lymphatic vessels in humans and mice, which has impacted research on neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis, neuropsychiatric disorders, such as anxiety, and neurodevelopmental disorders such as autism and Rett syndrome.

Hanzhang Lu, Ph.D., Session Co-Chair
Johns Hopkins University

Dr. Lu is an internationally recognized leader in physiological MRI. He has published over 240 peer-reviewed journal articles with an h-index of 66 and a total citation of >18,000. He is an associate editor of Frontiers in Neuroscience — Brain Imaging Methods, and he serves on the editorial boards of NeuroImage and NMR in Biomedicine. He has also been a guest editor of special issues on physiological MRI.

Dr. Lu was a charter member of the National Institutes of Health (NIH) medical imaging review panel, and he chaired several NIH study sections — including one on biomedical imaging technology — and high-end instrumentation and special emphasis panels. Dr. Lu's research focuses on development of MRI techniques to understand brain physiology and pathophysiology. He is a fellow of the International Society for Magnetic Resonance in Medicine (ISMRM), a fellow of the American Institute for Medical and Biological Engineering, and a distinguished investigator for the Academy for Radiology & Biomedical Imaging Research.

Hanzhang Lu was the chair of the ISMRM perfusion study group. He served on the ISMRM's Annual Meeting Program Committee, Trainee Stipend Committee, Awards Committee, and he was the program director of the ISMRM fMRI Study Group in 2011 and 2012. He was a lead organizer of the Brain at Work plenary session during the ISMRM annual meeting in Honolulu in 2017, and he chaired an ISMRM-sponsored workshop on functional MRI in Charleston, South Carolina, in 2014, and an ISMRM-sponsored workshop on Perfusion in Los Angeles, California, in 2022. He also chaired the organizing committee for the 2019 Imaging Cerebral Physiology Symposium.

In the Johns Hopkins Department of Radiology and Radiological Science, Dr. Lu serves as the director of the MRI Service Center and chief of the neurofunction section in the MR research division. He is also the chair of the RORA Oversight Committee, and he has been a member of the department's committees on CDAC, the Lunch and Learn Lecture Series, research joint chiefs of staff, Research Day organizing and pilot grant review.

Farah Lubin, Ph.D., Session Co-Chair
University of Alabama at Birmingham

Dr. Lubin received her undergraduate degree from Alabama State University in Montgomery, Alabama and her Ph.D. in Cell/Molecular Biology and Immunology from Binghamton University in Binghamton, New York. She has also worked as a research assistant at Memorial Sloan Kettering Cancer Center in New York. Dr. Lubin has completed two postdoctoral fellowships in Molecular Neuroscience at Baylor College of Medicine in Houston, Texas and most recently in the Department of Neurobiology at UAB. Dr. Lubin is a recipient of a Pathway to Independence Award from the National Institutes of Health (NIH/NIMH) and FASEB Award.

Dr. Lubin's main research work is focused on investigating the molecular and genetic basis of learning, memory and its disorders. The goal of these studies is to elucidate the role of genetic and epigenetic mechanisms in the on and off regulation of gene transcription during the consolidation of memory. These studies will provide novel insights into novel candidate transcriptional mechanism that may be involved in abnormal regulation of genes underlying memory deficits associated with neurological disorders such as epilepsy and Alzheimer's disease.

Kathleen Poston, M.D. M.S., Session Co-Chair
Stanford University

Dr. Kathleen Poston is the Edward F. and Irene Thiele Pimley Professor in Neurology and Neurological Sciences and (by courtesy) Neurosurgery at Stanford University. She received her Bachelor of Science in Bioengineering at the University of Pennsylvania, her Master's Degree in Biomedical Engineering and her M.D. at Vanderbilt University. She completed her Neurology residency training at UCSF, completed a fellowship in clinical Movement Disorders at Columbia University and post-doctoral research training in Functional Neuroimaging at the Feinstein Institute.
Dr. Poston's research and clinical emphasis is biomarker development to study the motor and non-motor impairments symptoms, such as dementia, that develop in patients with Parkinson's disease and Lewy body dementia. Dr. Poston is Chief of the Movement Disorders Division and holds an appointment in the Memory Disorders division. She is a founding member of the Stanford Alzheimer's Disease Research Center and co-Director for the Lewy Body Dementia Association Research Center of Excellence at Stanford University, and Director of the Stanford Parkinson's Foundation Center of Excellence.

David Wolk, M.D., Session Chair
University of Pennsylvania Perelman School of Medicine

Dr. David Wolk is Professor of Neurology, Chief of the Division of Cognitive Neurology, Director of the National Institute of Aging funded Penn Alzheimer's Disease Research Center, Co-Director of the Penn Institute on Aging, and Co-Director of the Penn Memory Center.

Dr. Wolk's primary clinical interest has been in the diagnosis and care of individuals with a variety of neurodegenerative conditions. His research has focused on the cognitive neuroscience of memory decline associated with aging and Alzheimer's Disease using techniques including behavioral testing, structural and functional MRI, and FDG and molecular PET imaging. Much of this work is also directed at examining biomarkers, including behavioral and neuroimaging, that differentiate healthy aging from the earliest transition to AD and their potential role in understanding disease mechanisms and incorporation into treatment trials. Another related thread of his work has been to better understand, classify and predict sources of heterogeneity in AD. Dr. Wolk has had sustained NIH support since 2003 and has been the principal or co-investigator on numerous local, national and international studies, including therapeutic trials.

Dr. Wolk completed his medical training at Johns Hopkins University, a Neurology residency at the University of Pennsylvania, and clinical Fellowship training in Cognitive and Behavioral Neurology at Brigham and Women's Hospital/Harvard Medical School; where he also completed a post-doctoral research fellowship studying memory in Alzheimer's Disease. Amongst a number of honors, he is the recipient of the American Academy of Neurology's Norman Geschwind Prize in Behavioral Neurology.

4. PANELISTS (IN ALPHABETICAL ORDER)

John Alam M.D.
CervoMed, Inc.

Dr. Alam serves as the Chief Executive Officer at CervoMed, co-founding the company (formerly known as EIP Pharma) in 2014. John is an industry leader in translational medicine with over 30 years of experience creating value to help build companies through clinical development success.

Until May 2014, he was therapeutic area head for diseases of aging at Sanofi, where he led all discovery and development activities directed at Alzheimer's disease, as well as a number of other age-related diseases including sarcopenia/frailty, osteoarthritis, chronic pain and many others. From 1997 to 2008, he held positions of increasing responsibility at Vertex Pharmaceuticals, including Chief Medical Officer and Executive Vice President, Medicines Development. At Vertex, he played major roles in the development of novel innovative medicines for HIV, Hepatitis C and Cystic Fibrosis. Prior to Vertex, Alam led clinical development of Avonex (interferon beta-1a) for multiple sclerosis at Biogen from 1991 to 1997.

John is a member of the board of directors of the Alliance for Aging Research (AAR), a Washington, D.C. based non-profit organization dedicated to promoting innovation to address the healthcare needs of older Americans. He received a M.D. from Northwestern University School of Medicine and a BS in Chemical Engineering from the Massachusetts Institute of Technology. In addition, he completed an internal medicine residency at Brigham and Women's Hospital and a post-doctoral fellowship at Dana-Farber Cancer Institute.

Miguel Arce-Renteria Ph.D.
Columbia University

Dr. Arce-Renteria is a bilingual cultural neuropsychologist. My research program investigates the sociocultural and environmental determinants of disparities in cognitive aging and Alzheimer's disease and related dementias (ADRD) primarily among the Hispanic/Latino/Latinx communities (hereafter Latinx). His current research focus has been on determining factors of reserve and resilience to ADRD among Latinx adults such as understanding the role of bilingualism. Leveraging his training as a clinical neuropsychologist, another extension of his research program has been to work with international studies of cognitive aging leading efforts with the

harmonization of cognitive data and development of diagnostic algorithms for the classification of mild cognitive impairment and dementia.

Dr. Arce-Renteria's work leverages ongoing studies of cognitive aging both within the United States (i.e., the Washington Heights Inwood Columbia Aging Project [WHICAP], the Offspring Study, and the REasons for Geographic and Racial Differences in Stroke [REGARDS] study), and internationally (i.e., Mexican Health and Aging Study [MHAS], Longitudinal Aging Study in India Diagnostic Assessment of Dementia [LASI-DAD] and others associated with the Harmonized Cognitive Assessment Protocol (HCAP) Network) to better understand the sociocultural factors associated with cognitive risk and resilience across Latinx individuals residing in the US and abroad.

Konstantinos Arfanakis, Ph.D.
Rush University Medical Center

Dr. Arfanakis is Core Leader of the Biomarker/Neuroimaging Core of the Rush Alzheimer's Disease Center (RADC) and Professor of Diagnostic Radiology and Nuclear Medicine at Rush University Medical Center. He is also Professor in the Department of Biomedical Engineering and Director of the MRI Program at Illinois Institute of Technology. He has expertise in multi-parametric in-vivo and ex-vivo MRI in aging and dementia, MRI-pathology investigations, and brain atlas development. A large component of Dr. Arfanakis' current research focuses on the development of imaging biomarkers of age-related neuropathologies.

Regina Armstrong, Ph.D.
Uniformed Services University of the Health Sciences

Dr. Armstrong primary academic appointment is as Professor and Chair of Anatomy, Physiology, and Genetics in the F. Edward Hebert School of Medicine at USU. Dr. Armstrong holds secondary appointments in the Neuroscience and the Molecular and Cell Biology Graduate Programs. Dr. Armstrong received the faculty award for Outstanding Graduate Biomedical Educator from the School of Medicine in 2002. She served as Director of the USU Neuroscience Graduate Program from 2002-2008 before stepping down to establish the Center for Neuroscience and Regenerative Medicine (CNRM). The CNRM is a collaborative intramural research program of the Uniformed Services University of the Health Sciences (USU) with the National Institutes of Health (NIH) and the Walter Reed National Military Medical Center (WRNMMC). The CNRM focus is pre-clinical through clinical research to promote recovery from traumatic brain injury and to improve psychological health of service members.

Dr. Armstrong served as the Director of the CNRM from 2008-2017 and now serves as the CNRM Director of Translational Research.

Dr. Armstrong teaches in the first-year medical student module on the nervous system and in several graduate student courses. Dr. Armstrong's laboratory focuses on mechanisms of damage and repair in the brain and spinal cord. Research efforts in her laboratory have been funded through peer-reviewed competitive awards from the NIH, the National Multiple Sclerosis Foundation, and the Department of Defense. Dr. Armstrong's research program has focused on cellular and molecular mechanisms of neuroregeneration. This work has taken from developmental studies and applied the techniques and approaches to examine repair after disease or injury. More specifically, her lab has extensive experience in white matter injury in multiple sclerosis models and in single and repetitive closed head injury models of mild traumatic brain injury. Her research team uses diverse approaches including genetic mouse models, neural stem cell culture, immunohistochemistry, in situ hybridization, fluorescence imaging, magnetic resonance imaging and behavioral assessments. Their philosophy is that integrating data from multiple independent techniques will result in more in-depth understanding and improved translational potential. This work also utilized collaborations to include analysis of human neuropathological specimens to validate aspects of our animal model studies.

Juan "Jon" Toledo Atucha, M.D.
Houston Methodist Hospital

Dr. Toledo Atucha completed his medical school and first neurology residency at the University of Navarra in Spain, where he also completed his Ph.D. evaluating neurophysiological deep brain stimulation recordings in Parkinson's disease. He then moved to the University of Pennsylvania, working as a post-doctoral researcher and research associate evaluating neuropathological, imaging and biofluid biomarker data in people with dementia and movement disorders. Dr. Toledo then completed his neurology residency at Houston Methodist Hospital, followed by a movement disorders fellowship at the University of Florida. Dr. Toledo has published over 100 peer-reviewed papers and has co-authored the manuscripts defining the clinical diagnostic criteria for dementia with Lewy bodies (DLB) and the neuropathological criteria for the Lewy pathology, aging-related tau astrogliopathy (ARTAG), and primary age-related tauopathy (PART).

Sami Barmada, M.D., Ph.D.
University of Michigan Neuroscience Institute

Dr. Barmada received his Ph.D. in the Medical Scientist Training Program at Washington University in St. Louis and completed his neurology residency at the University of California, San Francisco (UCSF). During residency and continuing in a postdoctoral fellowship, he worked with Dr. Steve Finkbeiner at the Gladstone Institutes in San Francisco to establish faithful model systems for the study of ALS and FTD pathogenesis, including one of the first human neuronal models of familial ALS and FTD. Dr. Barmada moved to the University of Michigan as an Assistant Professor of Neurology in 2013 and was promoted to Associate Professor in 2020.

Dr. Barmada's research centers on critical abnormalities in RNA and protein metabolism in ALS and FTD, combining basic biology with translational research and technology development. Dr. Barmada serves on the executive advisory board of the Robert Packard Center for ALS Research, and acts on the scientific advisory boards of the Live Like Lou Foundation and Synapticure, Inc. He has taken an active role in their efforts to raise awareness of ALS in the community and participates in several local and national fundraising efforts. In recognition of the impact and promise of his original research, Dr. Barmada was awarded the Young Physician Scientist Award from the American Society for Clinical Investigation in 2014, and he received the distinguished Angela Dobson and Lyndon Welch Research Professorship at the University of Michigan in 2015.

Staci Bilbo, Ph.D.
Duke University

Dr. Staci Bilbo is a leading American neuroimmunologist and the Haley Family Professor of Psychology and Neuroscience at Duke University. She is also a research affiliate at Massachusetts General Hospital, where she contributes to autism research at the Lurie Center. As the principal investigator of the Bilbo Lab, her work focuses on how early-life environmental challenges, particularly during the perinatal period, shape immune responses and influence brain development, cognition, and behavior.

Dr. Bilbo earned her B.A. in psychology and biology with high honors from the University of Texas at Austin in 1998, where she began her research, studying learning in frogs. She pursued graduate studies in neuroendocrinology at Johns Hopkins University under Dr. Randy Nelson, earning her M.A. in 2000 and Ph.D. soon after. Her early work examined how environmental and hormonal factors regulate immune responses, with several publications on seasonal and sex-specific immune adaptations in rodents.

She completed her postdoctoral work in neuroimmunology at the University of Colorado's Center for Neuroscience, focusing on the long-term effects of neonatal bacterial infection on memory. In 2007, she joined the faculty at Duke, where she led the Developmental Neuroimmunology Lab, studying glial biology and the lasting impact of early immune challenges on brain function.

In 2016, Dr. Bilbo joined Harvard Medical School and Massachusetts General Hospital as the Lurie Family Associate Professor and Director of Research at the Lurie Center. Her research expanded to include the effects of adolescent opioid exposure, prenatal pollutant exposure, and the role of microglia in adolescent social behavior.

She returned to Duke in 2019 while maintaining collaborative ties with Boston researchers. Dr. Bilbo is also an active member of the scientific community through editorial roles and is committed to outreach efforts promoting women in STEM.

Nicole Bjorklund, Ph.D.
Association for Frontotemporal Degeneration (AFTD)

Bringing together my expertise in biochemistry, translational neuroscience and biomarker development, I lead the RAPID-Dx alliance at Cohen Veterans Bioscience. The RAPID-Dx alliance is focused on advancing biomarker discovery and validation in post-traumatic stress disorder and traumatic brain injury.

Previously, I led the development and management of the Diagnostics Accelerator initiative at the Alzheimer's Drug Discovery Foundation, supporting the advancement of biomarkers for Alzheimer's disease and related dementias.

I started my career as an Assistant Research Professor and Operations Director of the Biomarker and Biorepository core facilities at Albert Einstein College of Medicine. My laboratories, as part of the CTSA-supported Institute of Clinical and Translational Research, supported the large number of clinical research studies at Einstein and Montefiore Medical Center in the Bronx, NY.

I completed my postdoctoral training at the University of Texas Medical Branch, where I investigated molecular resistance mechanisms to Alzheimer's disease. I earned a bachelor's degree in chemistry from Boise State University and a doctorate in biochemistry at Washington State University.

Bradley F. Boeve, M.D.
Mayo Clinic

Dr. Boeve is a consultant in the Department of Neurology and Center for Sleep Medicine at Mayo Clinic in Rochester, Minnesota. Dr. Boeve also serves as Enterprise Chair of the Division of Behavioral Neurology, Co-Investigator in the Mayo's Alzheimer's Disease Research Center, and Program Director for the Behavioral Neurology Fellowship Program. He joined the staff of Mayo Clinic in 1997 and holds the academic rank of Professor of Neurology, Mayo Clinic College of Medicine and Science. Dr. Boeve is recognized with the distinction of the Little Family Foundation Professorship in Lewy Body Dementia. His clinical and research interests include Alzheimer's disease, Parkinson's disease, and particularly the non-Alzheimer's degenerative dementias and the neurologically based sleep disorders.

His special interests are Lewy body disease/dementia, REM sleep behavior disorder, frontotemporal dementia +/- parkinsonism +/- ALS, primary progressive aphasia, corticobasal syndrome/corticobasal degeneration, progressive supranuclear palsy/Richardson's syndrome, among other disorders. He is a member of the Scientific/Medical Advisory Councils of the Lewy Body Dementia Association and Association for Frontotemporal Degeneration. He is co-PI of the North American Prodromal Synucleinopathy (NAPS) Consortium, co-PI of the Longitudinal Imaging Biomarkers of Disease Progression in DLB Protocol, co-PI of the Lewy Body Disease Functional Genomics Program, PI of the Coordinating Center of the Lewy Body Dementia Association Research Centers of Excellence Program, and co-PI of the ALLFTD Consortium focused on sporadic and familial frontotemporal lobar degeneration-spectrum disorders.

He is funded by the National Institute on Aging, National Institute of Neurological Disorders and Stroke, the Little Family Foundation, the Mangurian Foundation and the Turner Family Foundation. He has acted as co-editor of 3 books, co-authored over 40 book chapters and has contributed to over 600 papers in peer-reviewed journals.

Diane Bovenkamp, Ph.D.
BrightFocus Foundation

Dr. Bovenkamp is the Vice President of Scientific Affairs, and the chief scientist at BrightFocus Foundation, overseeing global operations of the organization's research programs. She serves as the scientific liaison in local, national, and international forums, and identifies and develops new research initiatives, partnerships, and funding policies consistent with the mission of BrightFocus.

Dr. Bovenkamp obtained her Ph.D. in Biochemistry from Queen's University in Kingston, Ontario, Canada, discovering and studying Eph receptors in angiogenesis and neural development in zebrafish and mice. She completed a Postdoctoral Fellowship in the Vascular Biology Program at Boston Children's Hospital/Harvard Medical School, isolating and characterizing zebrafish neuropilins. Dr. Bovenkamp conducted further research at the Johns Hopkins University Bayview Proteomics Center in the Division of Cardiology at Johns Hopkins School of Medicine in Baltimore, Maryland, using proteomic techniques for biomarker detection in human serum.

Adam L. Boxer, M.D., Ph.D.
University of California, San Francisco

Dr. Boxer is the Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF). He received his M.D. and Ph.D. from the New York University Medical Center Medical Scientist Training Program, completed a Neurology Residency at Stanford and a Neurobehavior Fellowship at UCSF.

Dr. Boxer directs the Neurosciences Clinical Research Unit and the Alzheimer's Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center. Dr. Boxer's research is focused on developing new treatments and biomarkers for neurodegenerative diseases, particularly those involving tau and TDP-43. He leads the Four Repeat Tauopathy Neuroimaging Initiative (4RTNI), a NIH-funded, multicenter, longitudinal tau PET and biomarker study focused on PSP and CBD. He is co-Principal Investigator of the ARTFL/LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) project, a new 18 site research network focused on preparing for FTLD clinical trials.

He has been the PI for a variety of multicenter, randomized, placebo controlled clinical trials in neurodegenerative diseases, including memantine for FTLD, davunetide for PSP, TPI-287 for primary and secondary tauopathies, a Phase 1b trial of gosuranemab for PSP, and salsalate for Alzheimer's Disease and PSP. He co-chairs the FTLD Treatment Study

Group (FTSG) and the PSP Research Roundtable, academic industry collaborative groups working to speed the development of new therapies for FTLD, CBD and PSP.

Candice M. Brown, Ph.D.
West Virginia University

The long-term research objective of my laboratory is to understand the neuroendocrine and neuroimmune mechanisms that control brain endothelial cell and blood-brain barrier responses to systemic inflammation. My research program addresses how prior acute systemic infections influence stroke severity and accelerate cognitive decline in mouse models of sepsis, ischemic stroke, and Alzheimer's disease. Our studies will provide insights into how sex differences shape innate inflammatory responses that, in turn, enhance neurological dysfunction and promote neurodegenerative disease.

Jeffrey M. Burns, M.D.
University of Kansas Medical Center

Dr. Burns is the Edward H. Hashinger Professor of Medicine and the Co-Director of the University of Kansas Alzheimer's Disease Research Center (KU ADRC). Dr. Burns also directs the Clinical and Translational Science Unit, the Department of Neurology's Memory Care Clinic, and leads the KU ADRC's Clinical Core and AD Trial Team, which is a site for the ADCS and ATRI national trial networks. Dr. Burns started the AD clinical research program at KU in 2004 to stimulate and support AD and aging research locally while pursuing research investigating how various lifestyle factors influence brain aging and AD. The program has grown into a vibrant research and training environment for AD and brain aging research. Dr. Burns has been continuously funded as a PI by the NIH since 2005 for work focused on how various lifestyle factors influence brain aging and AD progression.

Susan Catalano, Ph.D.
Capsida Biotherapeutics, Inc.

Dr. Catalano is a biopharmaceutical industry executive with 25 years of experience in strategic and operational scientific leadership of neurobiology, oncology and gene therapy drug discovery and development companies. She currently advises life science entrepreneurs, and consults as a seasoned executive and subject matter expert. She served as the Chief Scientific Officer & Advisor at Capsida and CODA Biotherapeutics, and co-founded Cognition Therapeutics where she was the Chief Science Officer and a member of the Board of Directors. Under Dr. Catalano's leadership, the company scaled from an idea through a full Phase 2 clinical program to an initial public offering in October 2021 (NASDAQ: CGTX).

In her early career, she held scientific leadership positions at Acumen Pharmaceuticals, Rigel Pharmaceuticals, and Roche. She is a recipient of the Pittsburgh Venture Capital Association Outstanding Entrepreneur Award, the Carnegie Science Center Entrepreneur Award, and the Ernst & Young Entrepreneurial Winning Women Award.

She has authored numerous publications and patents and served as principal investigator of several NIH preclinical and clinical awards. At the national level, Dr. Catalano actively participates on three NIH External Advisory Boards and two Editorial Boards for peer reviewed scientific journals. Susan received her B.A. from Barnard College/Columbia University and a Ph.D. in neurobiology from U.C. Irvine, with postdoctoral training at U.C. Berkeley and Caltech.

Alice Chen-Plotkin, M.D.
University of Pennsylvania

Dr. Chen-Plotkin is the Parker Family Professor of Neurology at the University of Pennsylvania. A Phi Beta Kappa graduate and English literature major at Harvard University, she began her scientific training as a Rhodes Scholar at Oxford University. At the Perelman School of Medicine at the University of Pennsylvania, she leads a research group studying the neurodegenerative diseases and maintains a clinical practice caring for Parkinson's Disease patients. She is the founding director of the Molecular Integration in Neurological Diagnosis (MIND) Initiative, an interdisciplinary effort launched in 2018 to develop precision medicine in the Penn Parkinson's Disease clinic. Dr Chen-Plotkin has won top awards from the American Academy of Neurology (Jon Stolk Award, 2014), the American Neurological Association (Derek Denny Brown Award, 2018), and the Doris Duke Foundation (Paragon Award, 2023) for her translational research efforts.

Joshua Chodosh, M.D., MSHS
New York University Grossman School of Medicine

Dr. Chodosh holds the inaugural endowed Michael L. Freedman Professor of Geriatric Research in the Division of Geriatric Medicine and Palliative Care in the Department of Medicine at NYU School of Medicine. He is Professor of Medicine and Population Health at NYU and Director of the Freedman Program on Aging and Cognition. He is also a core investigator in the VA HSR&D program at the Manhattan VA. Dr. Chodosh is a former Robert Wood Johnson Clinical Scholar and was on faculty as a Professor of Medicine at UCLA until he was recruited to NY in 2015. He has held a number of leadership roles both regionally and nationally focused on healthcare policy impacting on the quality of care for patients with chronic disease, particularly those with dementia.

Dr. Chodosh served as Chair of the State of California Alzheimer's and related Dementias Advisory Committee and co-chaired a statewide effort leading to the California State Plan for Alzheimer's disease. The California Plan has provided a model for other state plans and the National Alzheimer's Project Act. Dr. Chodosh is a member of the Journal of the American Geriatrics Society Editorial Board and he has published on quality of care for dementia and other chronic disease conditions, while leading multiple implementation trials.

Dr. Chodosh initiated a VA dementia assessment and care management program (V-CAMP) using clinical video-telehealth for rural-based Veterans with dementia that is poised to spread nationally. In addition to being an NIH-funded investigator, Dr. Chodosh is co-Director of a $7.5 million State of NY Department of Health service grant to develop and coordinate caregiver services for family members of those with dementia living in all five boroughs of New York City.

Ana Maria Cuervo, M.D., Ph.D.
Albert Einstein College of Medicine

Dr. Cuervo is the Robert and Renee Belfer Chair for the Study of Neurodegenerative Diseases, and professor in the Departments of Developmental and Molecular Biology and of Medicine of the Albert Einstein College of Medicine. She is also co-director of the Einstein Institute for Aging Studies. Dr. Cuervo's group is interested in understanding how altered proteins can be eliminated from the cells. Her group has recently linked alterations in lysosomal protein degradation with different neurodegenerative diseases including Parkinson's, Alzheimer's and Huntington's disease.

Dr. Cuervo is considered a leader in the field of protein degradation and was the recipient of the 2005 P. Benson Award in Cell Biology, the 2005/8 Keith Porter Fellow in Cell Biology, the 2006 Nathan Shock Memorial Lecture Award, the 2008 Vincent Cristofalo Rising Start in Aging Award, the 2010 Bennett J. Cohen Award in Basic Aging Biology and the 2011 Marshall Horwitz Prize for excellence in research. She is currently a member of the NIH Scientific Council of Councils.

Bernadette D'Alonzo Ph.D., MPH
University of Pennsylvania

Dr. D'Alonzo is a first-year postdoctoral research fellow in the Neurology Department at the University of Pennsylvania (Penn), with NIH NINDS brain injury training grant support. She received her PhD in Epidemiology from Penn in Spring 2024, where she used epidemiologic and qualitative methods to identify factors related to recovery among collegiate athletes with sport-related concussion. As part of her postdoctoral research, she is evaluating the role of interpersonal factors (e.g., social relationships/ social engagement and social isolation) on long-term cognitive and ADRD outcomes after TBI in an aging cohort, and she also focuses on the health of spouse-caregivers as members of an injured individual's social network. Dr. D'Alonzo's long-term goals are to help develop and lead well-designed, novel epidemiologic and mixed-methods studies to gain insights into underlying mechanisms contributing to TBI outcomes across the life course including ADRD, and to incorporate the role of socio-behavioral and interpersonal factors in this work.

Penny Dacks, Ph.D.
Association for Frontotemporal Degeneration (AFTD)

Dr. Dacks is Senior Director of Scientific Initiatives at AFTD where she leads strategy for AFTD's research programs. On behalf of AFTD, she serves as President of the FTD Disorders Registry LLC. Previously, she worked at the American Epilepsy Society, overseeing mission-related programs in research, medical education, and clinical activities, and the Alzheimer's Drug Discovery Foundation, leading development of CognitiveVitality.org and the Aging & Alzheimer's Prevention Program to source and evaluate potential therapies. She trained in neuroscience with a Ph.D. and postdoctoral fellowship at the University of Arizona and the Icahn School of Medicine, Mount Sinai.

Kristophe Diaz, Ph.D.
CurePSP, Inc.

Dr. Diaz is the Executive Director and Chief Science Officer of CurePSP, a national charitable foundation focusing on Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Multiple System Atrophy (MSA), three prime of life neurodegenerative diseases with biological mechanisms common to Alzheimer's and Parkinson's diseases. Dr. Diaz leads CurePSP, its programs, and partnerships to continue building the 3 foundational pillars of the organization: providing information, support, and financial aid to those living with PSP, CBD, and MSA (Care), increasing awareness and education to accelerate diagnosis (Consciousness), funding research while building enabling collaborations to advance critical discoveries towards new leads, new biomarkers, and treatments (Cure).

Dr. Diaz works closely with patients, care partners, advocates, scientists, clinicians, biopharma companies, governmental agencies, and other foundations, to make sure important advances and innovative technologies in neuroscience also address the unmet needs critical to PSP, CBD, and MSA. Prior to joining CurePSP, Dr. Diaz led multidisciplinary neuroscience programs at Cohen Veterans Bioscience, a nonprofit organization founded by industry veterans focused on solving trauma-related brain disorders. He received his Ph.D. in molecular and cellular biology at the University of Massachusetts, Boston. CurePSP is headquartered in New York City.

Aisha Dickerson, Ph.D.
Johns Hopkins University

Dr. Dickerson is a Bloomberg Assistant Professor of American Health in Environmental Challenges in the Department of Epidemiology. An environmental epidemiologist, Dr. Dickerson's primary research interests are in environmental risk factors for neurodevelopmental and neurodegenerative disorders, such as autism spectrum disorder and dementia.

Her research focuses on evaluating combined environmental and occupational exposures to metals and subsequent individual and transgenerational outcomes. She also investigates the influence of disparities in autism assessment and service provision along with environmental injustice in underserved communities.

Dr. Dickerson completed a year of postdoctoral training in the U.S. Environmental Protection Agency and held a postdoctoral fellowship in the Departments of Epidemiology and Environmental Health at the Harvard T.H. Chan School of Public Health.

Brittany N. Dugger, Ph.D.
University of California, Davis

Dr. Dugger has served as an interface throughout her career to the fields of neurology and neuropathology, resulting in more than 60 peer-reviewed manuscripts and numerous private, state, and federally funded grants. Dr. Dugger earned her Bachelor of Science from Michigan State University. She went on to obtain her Ph.D. from Mayo Clinic Graduate School, where she became fascinated by the selective vulnerability of neuropathologies through her thesis work under the direction of Dr. Dennis Dickson. She then completed a postdoctoral fellowship under Dr. Thomas Beach, being promoted to an independent staff scientist at the Banner Sun Health Research Institute, aiding in a research-based human autopsy program.

In 2015, she was recruited by Dr. Stanley Prusiner to serve as the neuropathology core leader for academic and drug discovery groups within the Institute of Neurodegenerative Diseases at the University of California San Francisco. In 2018, she became an assistant professor of Pathology at the University of California Davis. In addition to running her own laboratory she supports the University of California Davis-Alzheimer's Disease Center as a neuropathology core leader alongside Dr. Lee-Way Jin, Professor and Director of Neuropathology.



Brian Edlow, M.D.
Massachusetts General Hospital at Harvard Medical School

Dr. Edlow received his B.A. from Princeton University and M.D. from the University of Pennsylvania School of Medicine. He completed an internal medicine internship at Brigham and Women's Hospital (BWH), followed by neurology residency and neurocritical care fellowship at Massachusetts General Hospital (MGH) and BWH.

He is currently a critical care neurologist at MGH, where he is Co-Director of Mass General Neuroscience, Associate Director of the Center for Neurotechnology and Neurorecovery, and Director of the Laboratory for NeuroImaging of Coma and Consciousness.

David Fardo, Ph.D.
University of Kentucky

Dr. Fardo is a professor, and the inaugural Stephen W. Wyatt Endowed Professor of Public Health. He serves as an Affiliate Faculty in the Sanders-Brown Center on Aging and as co-Investigator in the National Institute on Aging (NIA)-funded UK Alzheimer's Disease Research Center (ADRC).

Dr. Fardo is currently the principal investigator of two awards from the NIA, researching genetic risk factors contributing to various neuropathological endophenotypes and multiple neurodegenerative diseases. His currently funded collaborative work ranges from therapeutic targeting of the genes TREM2 and SHIP1 for AD to investigating novel pathogenetic mechanisms for hippocampal sclerosis and risk factors for conversion to mixed dementias.

He has developed several courses across the spectrum of CPH degree programs and offers graduate courses in statistical genetics. He has served in various roles including as an Academic Leadership Academy Fellow and Chair of CPH Faculty Council and the Appointment, Promotion and Tenure Committee at the University of Kentucky.

Nicolas Fawzi, Ph.D.
Brown University

Dr. Fawzi's work centers on determining the structure, dynamics, interactions of large assemblies of intrinsically disordered proteins. In particular, we focus on 1) protein aggregates implicated in Alzheimer's Disease and 2) liquid-liquid phase separated forms of RNA-binding proteins associated with inclusion formation in amyotrophic lateral sclerosis (ALS / Lou Gehrig's disease) and frontotemporal dementia. He received undergraduate degrees in bioengineering and marketing at the University of Pennsylvania. He received a Ph.D. from the Joint Graduate Group in Bioengineering at the University of California, Berkeley and UCSF for his work with Teresa Head-Gordon on molecular simulation of protein aggregation and completed postdoctoral training in the group of G. Marius Clore at the National Institutes of Health in biomolecular NMR spectroscopy of protein association and aggregation. Nicolas Fawzi joined the faculty at Brown in January 2013.



Joseph Thomas Flies-Away, MPA, J.D.
Community Nation Building Consultant

Joseph Thomas Flies-Away, MPA, J.D. (Hualapai), formerly served as Chief Judge of the Hualapai Tribal Court and as pro tem judge for several tribal courts in the Southwest. Currently he works as a Community Nation Building Consultant in Phoenix, Arizona. As a consultant, Flies-Away facilitates tribal community & nation-building projects in planning, evaluation, technical assistance, research, and training. Focusing on developing justice systems, including Healing to Wellness Courts, Flies-Away is interested in how courts and other governmental institutions contribute to effective governance and 'living together well'.

Flies-Away's experience includes serving as a Hualapai Tribal Council Member, Director of the Tribe's Department of Planning & Community Vision, promoter and Chairman of the Board of the tribal corporation, HBE, Inc., and Chief Judge and Associate Judge of the Hualapai Tribal Court (trial court) and Associate Justice and Chief Justice of the Hualapai Court of Appeals.

Flies-Away has also taught students from Junior High to University, including Lecturer in Law at Stanford University School of Law, Adjunct Faculty at Arizona Summit Law School, and in Native American Studies in the Stanford School of Humanities & Sciences, Arizona State, and a UCLA course called Working in Indian Country. Flies-Away holds a Juris Doctor degree from the Sandra Day O'Connor College of Law, a Master's Degree in Public Administration from Harvard's Kennedy School of Government, and is a graduate of Stanford University in English Literature.

Nicole Fowler, Ph.D., MHSA
Indiana University School of Medicine

Dr. Fowler is a health services researcher and implementation scientist whose overarching focus is on behavioral and other nonpharmacologic approaches to support dementia care and family caregiving.

Dr. Fowler's research is focused on the development, testing, and comparison of evidence-based and patient-centered interventions that improve the quality of care for older adults with Alzheimer's disease and their family caregivers, in particular medical decision-making interventions to support family caregivers. Her research is funded by the National Institute on Aging, and the U.S. Department of Defense.

Dr. Fowler is committed to advancing research that will have immediate relevance to patients and families faced with health care choices. The goals of her research are to help clinicians better integrate and apply evidence-based care to older adults with dementia and to help policymakers identify better ways to measure and promote quality care for older adults in all health care settings.

Bess Frost, Ph.D.
Brown University

Dr. Frost is the Bartell Zachry Distinguished Professor for Research in Neurodegenerative Disorders at the Barshop Institute for Longevity and Aging Studies, the Glenn Biggs Institute for Alzheimer's and Neurodegenerative Disorders, and the Department of Cell Systems and Anatomy at the University of Texas Health San Antonio. Dr. Frost earned her Ph.D. from the University of California San Francisco in the laboratory of Dr. Marc Diamond, where she pioneered the initial studies demonstrating that pathogenic forms of tau have prion-like properties. Dr. Frost performed her postdoctoral training at Harvard Medical School in the laboratory of Dr. Mel Feany, where she developed a multi-system approach to studying tauopathy, interweaving studies in Drosophila, mouse and human brain tissue.

The research focus of Dr. Frost's laboratory revolves around the basic neurobiology connecting toxic forms of tau to neurotoxicity. Dr. Frost's contributions to neurodegenerative disease research have earned her an O'Donnell Award in Medicine from The Academy of Medicine, Engineering and Science of Texas and a Standout Achievement Award from CurePSP. The Frost laboratory has discovered that the detrimental effects of pathogenic tau on nuclear and genomic architecture activate retrotransposons and alter RNA metabolism. Through this work, they have identified new targets for therapeutic development, as well as compounds that interfere with these processes and suppress tau-induced neuro-

toxicity. Based on these findings, Dr. Frost and her team have recently initiated a Phase IIa clinical trial in which they are testing antiretroviral therapy in patients with early Alzheimer's disease.

Douglas Galasko, M.D.
University of California, San Diego

Dr. Galasko is a Neurologist who currently serves as Associate Director of the UCSD Shiley-Marcos Alzheimer's Disease Research Center (ADRC). In clinical practice, he provides comprehensive care for patients with memory and cognitive disorders, at the UCSD Memory Disorders Clinic. He also is a Staff Physician at the VA Medical Center, La Jolla.

Dr. Galasko has contributed to clinical, biomarker and therapeutic research in Alzheimer's disease and related disorders. He has authored over 400 journal articles and book chapters and serves as Editor-in-Chief of the journal Alzheimer's Research and Therapy. He has received research funding from the National Institute on Aging, the State of California, the Alzheimer Association, the Michael J. Fox Foundation and the Alzheimer's Disease Drug Discovery Foundation and has been an investigator in numerous industry-funded clinical trials.

David M. Gate, Ph.D.
Northwestern University Feinberg School of Medicine

Dr. David Gate received his Ph.D. from the University of Southern California in 2015. He then trained as a postdoctoral fellow with Tony Wyss-Coray at Stanford. In 2021, Dr. Gate became a faculty member in Neurology at Northwestern University in Chicago. Dr. Gate's laboratory employs multi-omics strategies to interpret immune system changes related to neurodegeneration. His group is particularly interested in the interplay between T cells and neurogenerative disease antigens.

Dr. Gate is a genomicist with a background in neuroimmunology. He and his colleagues were the first to isolate and sequence immune cells of the cerebrospinal fluid from patients with neurodegenerative disease. His laboratory has contributed to our understanding of the role of the immune system in neurodegenerative diseases, including Alzheimer's disease and Lewy body dementia.

Tamar D. Gefen, Ph.D.
Northwestern University Feinberg School of Medicine

Dr. Gefen received her Ph.D. from Northwestern University Feinberg School of Medicine in 2015. She then trained as a postdoctoral fellow at Northwestern University in clinical neuropsychology/neuropathology. She is an academic clinical neuropsychologist with an interest in neurodegenerative disorders and successful trajectories of aging (the Northwestern University SuperAging Program or "NUSAP"). She directs the Laboratory for Translational Neuropsychology at Feinberg School of Medicine at Northwestern, which attempts to bridge antemortem clinical features of dementia with postmortem microscopic neuropathology found at autopsy.

Dr. Gefen is the Co-Director of the Clinical Core of the NIA-funded (P30) Alzheimer's Disease Research Center (ADRC) housed within the Mesulam Center for Cognitive Neurology and Alzheimer's Disease. Her clinical work focuses on the neuropsychological characterization of dementia syndromes and other age-related disorders.

Paola Gilsanz, ScD
Kaiser Permanente

Dr. Gilsanz is a Research Scientist II at the Division of Research, Kaiser Permanente Northern California. Dr. Gilsanz earned her MPH from the University of California, Berkeley, and her doctorate from Harvard T.H. Chan School of Public Health. She is an epidemiologist focused on examining modifiable psychosocial and life course determinants of healthy brain aging. Her research pays special attention to possible differences in the timing, distribution, and effects of risk and protective factors by sex, gender, race, and ethnicity to better inform future public health interventions. She also leads research examining possible modifiable risk factors for dementia among individuals with type 1 or type 2 diabetes, a growing segment of the elderly population that is already at heightened dementia risk. Her research is driven by the quest for healthy brain aging for everyone.

Aaron D. Gitler, Ph.D.
Stanford University

Dr. Gitler is a professor in the department of genetics at Stanford University. He received his undergraduate training at Penn State University, a Ph.D. in cell and molecular biology at University of Pennsylvania and completed postdoctoral training with Dr. Susan Lindquist at the Whitehead Institute for Biomedical Research. He joined the faculty of University of Pennsylvania in 2007 and moved to Stanford University in 2012, where he is currently Professor of Genetics. Aaron's current area of interest is mechanisms of human neurodegenerative diseases.

Crystal M. Glover, Ph.D.
Rush University Medical Center

Dr. Glover is an applied social psychologist, mixed methodologist, and health equity in aging researcher at the Rush Alzheimer's Disease Center and an Associate Professor of Psychiatry and Behavioral Sciences (and) Neurological Sciences in Rush Medical College. She also leads the Outreach, Recruitment, and Engagement Core at the Rush Alzheimer's Disease Center. Dr. Glover's areas of interest include health equity and health disparities; structural and psychosocial determinants of health including socioeconomic status and psychological wellbeing; intersectionality as a conceptual framework and methodology; and social cognitive processes such as attitudes, beliefs, and perceptions.

Dr. Glover focuses her research and related efforts on understanding and facilitating cognitive and healthy aging across all demographic groups but with a special concentration on collaborating with and inclusion of members of African American/Black and Hispanic/Latino communities that have been inequitably included and traditionally understudied in aging research. She has widely published her peer-reviewed work in several high-impact scientific journals, including Alzheimer's & Dementia: The Journal of the Alzheimer's Association, CHEST, and Human Genetics. She continues to present her research at international and national scientific meetings, and belongs to several professional groups, including The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) and the Centers for Disease Control and Prevention BOLD Public Health Center of Excellence on Dementia Risk Reduction. Overall, Dr. Glover dedicates her work to eradicating health disparities and creating health equity - globally, nationally, and locally.

Danielle Graham, Ph.D.
Biogen

Dr. Graham received her Ph.D. from Baylor University. After her doctoral training, she completed a postdoctoral fellowship at the University of Texas Southwestern Medical Center in Dallas, TX characterizing the role of BNDF and CREB in the mesolimbic DA system in neuropsychiatric illness. Dr. Graham moved to Boston MA in 2007 to join the Neurobiology department at Merck Research Labs. As a research biologist at Merck, she contributed to the early-stage drug discovery pipeline through the development of novel pharmacodynamic and efficacy models of CNS Disease. In 2009, she moved to EM.D. Serono and joined the Translational Neuropharmacology group. At EM.D. Serono, she was responsible for leading a team of scientists in the characterization of novel therapeutics and biomarker endpoints for AD, PD, and MS. In 2014, she moved to Biogen and joined the Translational Sciences group at Biogen where she has had roles with increasing responsibility over the years. At present, Dr. Graham is Vice President, Head of Fluid Biomarkers and Bioanalytics at Biogen. Dr Graham and her team played a critical role in the recent accelerated approval of Tofersen, a novel therapy in SOD1 ASO. Tofersen was granted accelerated approval based on the data generated on neurofilament indicating NfL is a surrogate endpoint reasonably likely to predict clinical benefit.

Neil Graham, MRCP, Ph.D.
Imperial College of London

Dr. Graham is a NIHR Clinical Lecturer in Dementia within the Department of Brain Sciences and the UK Dementia Research Institute Centre for Care Research and Technology at Imperial College London. As a neurologist (MRCP UK Neurol.) he practices clinically at Imperial College Healthcare NHS Trust.

Neil read medicine at Sidney Sussex College, Cambridge and University College London, trained in neurology in West/ Central London, and completed his Ph.D. with Prof David Sharp at Imperial College in 2021.

His main scientific interest is in understanding how trauma to the brain relates to long-term neurodegeneration and dementia, using tools such as advanced fluid biomarkers and neuroimaging. His work is published in a range of academic journals such as Science Translational Medicine, Brain and Alzheimer's & Dementia, and has been covered in media outlets including the Economist, Wired, Evening Standard, Private Eye and BBC Radio 4.

David Gutman, M.D., Ph.D.
Emory University School of Medicine

David Gutman, M.D., Ph.D. is an associate professor in the Department of Biomedical Informatics at Emory University School of Medicine. Dr. Gutman joined the faculty at Emory in 2009. As a research scientist in the Center for Comprehensive Informatics (CCI), he is gaining expertise in whole slide digital imaging.

Dr. Gutman is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute. Dr. Gutman received his Ph.D. in Neuroscience in 2005 and M.D. from Emory University in 2005. He completed his residency in Psychiatry at Emory University in 2009.



Laurence B. Guttmacher, M.D.
University of Rochester, School of Medicine and Dentistry

Dr. Guttmacher is in the early stages of Lewy Body Disease. After a fellowship in neuropharmacology at NIMH, he returned to the University of Rochester where he is now an Emeritus Professor of Psychiatry and Health Humanities. At various times, he has been an Associate Dean in the medical school, the Residency Director in psychiatry, and the Clinical Director at Rochester Psychiatric Center. Suspicious about his increasing difficulty encoding new information, he went to NINDS where he received a magnificent workup and learned that he was alpha-synuclein positive.

After reading others' accounts of their dementing processes, he decided that remaining quiet about what he was experiencing served only to reinforce the stigma. He then wrote about his experience in Lancet Psychiatry and gave a Grand Rounds in his home department. He continues to teach residents and medical students, volunteers at a free clinic, codirects a film series on mental illness and recovery and continues to hike and play basketball. He will once again play in the National Senior Games this summer.

Scott Hamilton

Scott helps take great ideas for social good to scale, drawing on what he learned from his time in government, philanthropy, and business, as well as launching four education start-ups with an outstanding track record of results. He is now helping create a nationwide collaborative of clinics for the post-acute care of traumatic brain injury. Early in his career, Scott held posts in the White House, with the U.S. Secretary of Education, and as the Associate Commissioner of Education for Massachusetts.

Carl V. Hill, Ph.D., MPH

Alzheimer's Association

Dr. Hill is the chief diversity, equity and inclusion officer for the Alzheimer's Association®, overseeing strategic initiatives to strengthen the Association's outreach to all populations, and providing communities with resources and support to address the Alzheimer's crisis. Dr. Hill authored an editorial in the Journal of New England Medicine (JAMA) Neurology highlighting the need for more diverse perspectives to address disparities and pursue equity in dementia science. Dr. Hill earned his Ph.D. from the University of Michigan School of Public Health, where he trained with the Center for Research on Ethnicity, Culture and Health (CRECH) and the Program for Research on Black Americans (PRBA). He is an alumnus of the National Medical Fellowships Inc./W.K. Kellogg Foundation Health Policy Fellowship Program. Dr. Hill holds a master's degree in public health from Morehouse School of Medicine, and he received its Distinguished Alumnus Award in 2019. As a member of the Centers for Disease Control and Prevention's (CDC) Public Health Prevention Service, a training and leadership program, he helped to establish the Center for Bioethics in Research and Healthcare at Tuskegee University.

Timothy J. Hohman, Ph.D.
Vanderbilt University Medical Center

Dr. Hohman is a Professor of Neurology, cognitive neuroscientist, and computational geneticist, with secondary appointments in the Vanderbilt Genetics Institute and Department of Pharmacology. Dr. Hohman's research leverages advanced computational approaches from genomics, proteomics, and neuroscience to identify novel markers of Alzheimer's disease risk and resilience. Dr. Hohman is the Vanderbilt Alzheimer's Disease Research Center Biomarker Core Leader, oversees the development of neuroimaging, proteomic, and big-data analytical pipelines at the Vanderbilt Memory and Alzheimer' Center, and is the Principal Investigator of the Computational Neurogenomics Team focused on Alzheimer's Resilience and Sex Differences. Outside of Vanderbilt, he has directed numerous multi-site collaborative initiatives, with as many as four analysis sites and 40+ contributing universities. Dr. Hohman directs the Genomics Core for the Preclinical Alzheimer's Disease Consortium and is co-chair of the Alzheimer's Disease Sequencing Project (ADSP) Harmonization Consortium.

Dr. Hohman received his BA in Psychology (magna cum laude) from Gordon College, followed by his MA in Psychology from American University. He received his doctoral degree in neuroscience from American University focusing on cognitive and neural changes during normal aging. He also completed a fellowship as part of the National Institutes of Health Graduate Partnership Program in the Laboratory of Behavioral Neuroscience at the National Institute on Aging. He completed his postdoctoral training at Vanderbilt where he was a T32 postdoctoral research fellow as part of the Neurogenomics training program in 2012, a recipient of the Pharmaceutical Research and Manufacturers of America Foundation postdoctoral fellowship in translational medicine and therapeutics in 2013, and a K12 Building Interdisciplinary Research Careers in Women's Health Scholar in 2013.

David Holtzman, M.D.
Washington University School of Medicine in St. Louis

Dr. Holtzman received his BS (1983) and M.D. (1985) from Northwestern University followed by a Neurology residency at UCSF from 1985-1989. He did post-doctoral research at UCSF from 1989-1994. He moved to Washington University in 1994 as an Assistant Professor and was Chair of Neurology at Washington 20 | Page University from 2003-2021. He is currently Professor of Neurology, scientific director of the Hope Center for Neurological Disorders, and Associate Director of the Knight ADRC.

Some of his lab's accomplishments include showing in part how APOE contributes to AD, development of biomarkers for AD, demonstration that synaptic activity and sleep affect Aß and tau levels in vivo, describint the effects of APOE, TREM2, and microglia on tau-mediated neurodegeneration, and development of an anti-Aß antibody in a phase III secondary prevention trial for AD (A4) and an anti-ApoE antibody being developed for human trials.

Several of his honors include being a recipient of the Potamkin prize and MetLife award for research on Alzheimer's disease, Rainwater Prize for outstanding innovation in neurodegenerative disease research, election to the National Academy of Medicine, election to the National Academy of Inventors, being appointed to the National Advisory council of the NINDS and NIA, the Chancellor's award for innovation and entrepreneurship and the Carl and Gerty Cori award from Washington University, elected Fellow of the AAAS, and being past president of the American Neurological Association. Holtzman has trained over 70 graduate students, post-doctoral fellows, and physician-scientists, many of whom have gone on to successful careers in academia and industry.

Virginia Howard, Ph.D.
University of Alabama at Birmingham

Dr. Howard is a Distinguished Professor of Epidemiology at the School of Public Health at the University of Alabama at Birmingham (UAB). She received a MSPH degree in Biostatistics from UNC-Chapel Hill and her Ph.D. in Epidemiology from MUSC. She is a stroke epidemiologist with over 30 years' experience in multicenter, multidisciplinary clinical trials and longitudinal cohort studies with a focus on stroke, stroke risk factors, cognitive functioning, and health disparities. Dr. Howard has 450+ publications and an h-index of 98+. She is one of the lead epidemiologists of the long-running NINDS/NIA co-funded REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study started in 2001, and PI or co-I of many REGARDS ancillary studies. She is a co-investigator, member of the Analysis Core and mentor on UAB's Deep South RCMAR (Resource Center for Minority Aging Research) funded by NIA. She has been PI of the statistical and data coordinating center or the leading clinical trial epidemiologist contributor for five major stroke primary or secondary prevention multicenter clinical trials.

Dr. Howard has been a member of the editorial board for the International Journal of Stroke since 2013, the AHA Stroke journal since 2020, and in 2023, she was invited to join the Methodology and Statistics editorial board for the journal Neurology. She has served on numerous NIH and American Heart Association review committees and advisory committees, including most recently the NINDS Steering Committee on Health Disparities, and the subcommittee on Workforce Diversity and Health Disparities, and chairperson of the AHA Heath Equity Research Network on Rural Health. Her research program has included sex differences in the impact of risk factors on stroke risk, and childhood exposures/quality of education on stroke risk and cognitive function, and she was recently awarded an NIH conference grant for Advancing the Study of Stroke in Women to be held in April 2024.

Gareth Howell, Ph.D.
The Jackson Laboratory

Dr. Howell is an Associate Professor and the Diana Davis Spencer Foundation chair for Glaucoma Research at The Jackson Laboratory (JAX). He is a member of the executive committee of the JAX Center for Alzheimer's and dementia research and a lead principal investigator of MODEL-AD. His research focuses on developing translationally relevant mouse models for neurodegenerative diseases including Alzheimer's disease, related dementias, and glaucoma. He then uses these models to identify strategies to manipulate inflammatory responses and vascular changes to treat these diseases. Before joining the JAX faculty in 2012, Dr. Howell received a Ph.D. in 2002 in comparative genomics and bioinformatics at the Wellcome Sanger Institute (Cambridge, UK) where he was part of the team that sequenced the first human genome. He was then a postdoctoral fellow at JAX (2003-2004) and The University of Sheffield, UK (2005) and then a Research Scientist at JAX (2005-2012).

Yadong Huang, M.D., Ph.D.
J. David Gladstone Institutes at University of California, San Francisco

Dr. Huang is a senior investigator at the Gladstone Institutes, where he is also the director of the Center for Translational Advancement and an investigator in the Roddenberry Stem Cell Center. In addition, he is a professor of neurology and pathology at UC San Francisco.

Huang earned an M.D. from Qingdao Medical University in China, and a Ph.D. in biochemistry and pathology from Peking Union Medical College and Chinese Academy of Medical Sciences in Beijing. He was trained as a postdoctoral fellow at the Arteriosclerosis Research Institute at the University of Muenster, Germany. Huang joined Gladstone Institutes in 1995 as a postdoctoral fellow and became a staff research investigator in 1999. In 2015, he was promoted to senior investigator.

Huang studies the pathogenesis of Alzheimer's disease, focusing on the roles of apoE4. His laboratory demonstrates that apoE4 is expressed in neurons, under injury or stress conditions, where it is proteolytically cleaved, leading to the generation of neurotoxic fragments that contribute to Alzheimer's disease. His laboratory also showed that expression of apoE4 causes age-dependent impairment of GABAergic interneurons in the hippocampus, learning to learning and memory deficits. He has been heavily involved in identifying strategies for the treatment or prevention of Alzheimer's disease by targeting

apoE4. Dr. Huang has published more than 130 scientific papers and has 12 patents. He is a scientific co-founder for two pharmaceutical companies: E-Scape Bio, Inc. and GABAeron, Inc.

Bistra Iordanova, Ph.D.
University of Pittsburgh, Swanson Engineering

Dr. Iordanova is an Assistant Professor at the University of Pittsburgh, Swanson School of Engineering, whose work focuses on multi-level translational studies of neurovascular and metabolic brain health with focus on aging and sex-specific differences. Her lab develops multimodal neuroimaging platforms to explore systems-level neurovascular and metabolic events during neurogenesis, normal development and neurodegeneration; with an interest in the life of brain cells inside living animals, particularly in the context of neuronal activity, oxygen and glucose metabolism. Recently, her research began to investigate the sex-specific changes in the brain metabolism and neurovascular health that drive differences in etiology, onset and progression of Alzheimer's disease with an aim to provide mechanistic insights into the neurometabolic and vascular deficits of vulnerable populations and motivate tailored therapeutics that can benefit all humans.

Linde Jacobs, RN

Starting from a very young age, Linde was immersed in the medical community and culture of "caring for others." She has been working in healthcare for the past 20 years, and before that, she accompanied her mother Allison to work, who was a physical therapist. From her first job as a Personal Care Attendant, she progressed into her CNA certificate, hospital volunteer, pediatric oncology clinic assistant, and then obtained her Bachelor of Nursing degree from Gustavus Adolphus College. In the last 15 years she has gained experience with people of all ages from birth to elderly; in hospitals, clinics, public health, and surgery centers.

Linde is a second-generation caregiver who watched and assisted caring for her grandmother, Beverly from a very young age. She then became her mother's primary caregiver when she subsequently developed symptoms of MAPT FTD when Linde was just 22. Linde learned to balance caring for her mother while starting off her young adult life with her first professional job, starting a family and becoming a mother herself. Despite the family history, her mother's journey with the disease was harrowing and faced many legal, financial, diagnostic, prejudicial battles until she passed away at the age of 62 in 2021. Shortly after her mother passed away, Linde learned that she would face the FTD journey

again, after genetic testing revealed that she was a positive genetic carrier for the MAPT gene.

Fueled by failures of her past, while also fearing her future, Linde began the direct role of FTD advocacy by deeply engaging herself in research studies across the United States; directly corresponding with top researchers working in FTD research; offering insight to government officials on current systemic issues; presenting to the NIH and FNIH; influential persons interviews; featured guest in blog posts, interviews, articles, podcasts; keynote conference speaker; and will be featured in an upcoming PBS documentary in 2025. All these efforts were made in honor of her mother, and to pursue a better future for her two young daughters who are at risk of inheriting this same genetic mutation from her.

Lee Jennings, M.D., MSHS, AGSF
Oklahoma University College of Medicine

Dr. Jennings, Chief and Associate Professor, Reynolds Section of Geriatric Medicine at the University of Oklahoma Health Sciences Center, is a board-certified geriatrician and health services researcher whose work focuses on improving models of care delivery for dementia, aligning care received with patient health goals, and improving the competency of health professions students to provide high quality geriatric care. She is the Principal Investigator for 3 statewide grants funded by HRSA, ACL, and the Reynolds Foundation focused on geriatric health care workforce development and community health education for older Oklahomans and their family caregivers. She is a co-investigator on research funded by PCORI, NIA, and the John A. Hartford Foundation and co-chairs the Women in Geriatrics Section for the American Geriatrics Society. Clinically, she specializes in comprehensive geriatric assessment and cognitive evaluation and sees patients at the OU Physicians Senior Health Clinic and the Oklahoma City VA Health System.

Gregory A. Jicha, M.D., Ph.D.
University of Kentucky College of Medicine

Dr. Gregory Jicha earned an M.D. from Albert Einstein College of Medicine in Bronx, New York, and completed a fellowship at the Mayo Clinic in Rochester, Minnesota. Dr. Jicha is certified by the American Board of Psychiatry and Neurology.

Dr. Jicha serves on the Executive Committee and is the Director of the Clinical Core of the University of Kentucky (UK) and the NIA-funded Alzheimer's Disease (AD) Center. He also directs the Telemedicine Cognitive Clinic at UK, designed to reach rural populations across Kentucky for clinical and research-related

activities in AD and related disorders. Dr. Jicha holds the Robert T. and Nyles Y. McCowan Endowed Chair in Alzheimer's Research at UK.

His current research interests lie in mild cognitive impairment, clinicopathological correlations in early preclinical disease states, and clinical trials of disease-modifying therapies for AD. He is the principle investigator at UK for the National Alzheimer's Disease Cooperative Study Group and serves on the Clinical Task Force and Steering Committee for the National Institute of Aging Alzheimer's Disease Center Program.

Victoria E. Johnson, MBChB, Ph.D.
University of Pennsylvania Perelman School of Medicine

Dr. Johnson is an Assistant Professor in the Dept. of Neurosurgery and Penn Center for Brain Injury and Repair at the University of Pennsylvania. Dr. Johnson received her medical degree and Ph.D. from the University of Glasgow, UK. She then completed a post-doctoral fellowship at the University of Pennsylvania Center for Brain Injury and Repair before also joining the faculty at Penn. Her primary research focus is understanding the chronic neuropathological sequelae of traumatic brain injury (TBI), including the potential links between TBI and progressive neurodegenerative disease. This includes the examination of human neuropathology chronically following TBI exposure, as well as utilizing preclinical models to explore the mechanisms driving trauma-related neurodegeneration. She also serves as a co-investigator on the NINDS funded Collaborative Neuropathology Network Characterizing Outcomes of Traumatic Brain Injuries (CONNECT-TBI) project.

Aimee W. Kao, M.D., Ph.D.
University of California, San Francisco

Dr. Kao is a Professor of Neurology at the University of California, San Francisco and the John Douglas French Foundation Endowed Professor. She leads an NIH-supported Tau Center Without Walls and directs the UCSF Tau Consortium Human Fibroblast Bank. Dr. Kao's clinical expertise includes the diagnosis and treatment of Alzheimer's disease, vascular dementia, Lewy body disease and frontotemporal lobar degeneration. Her basic science laboratory studies how age, stress and pH changes affect protein homeostasis and contribute to sporadic and familial neurodegenerative disorders. She has received the Paul G. Allen Family Foundation Distinguished Investigator Award in Neurodegenerative Diseases, the Glenn Award for Research in the Biological Mechanisms of Aging and the Derek Denny Brown Young Neurological Scholar Award.

Jason Karlawish, M.D.
University of Pennsylvania Perelman School of Medicine

Dr. Jason Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania Perelman School of Medicine. He is board-certified in geriatric medicine. He was educated at Northwestern University, the Johns Hopkins Medical Institutions, and the University of Chicago.

Dr. Karlawish is a Senior Fellow of the Leonard Davis Institute of Health Economics, Senior Fellow of the Penn Center for Public Health Initiatives, fellow of the University of Pennsylvania's Institute on Aging, director of the Penn Program on Precision Medicine for the Brain (P3MB), Co-Associate Director of the Alzheimer's Disease Research Center, and co-director of the Penn Memory Center. He is also director of the Alzheimer's Disease Research Center's Outreach, Recruitment and Education Core and the center's Research Education Component.

His research focuses on aging, neuroethics, and policy. He has investigated issues in dementia drug development, informed consent, quality of life, paradoxical lucidity and theory of mind in dementia, research and treatment decision-making, and voting by persons living with dementia. He is the project leader of makingsenseofalzheimers.org, a creative space for understanding the past, present and future of Alzheimer's disease. He is the author of The Problem of Alzheimer's: How Science, Culture and Politics Turned a Rare Disease Into a Crisis and What We Can Do About It, and the novel Open Wound: The Tragic Obsession of Dr. William Beaumont. His essays on ethics and aging have appeared in The Hill, The New York Times, Philadelphia Inquirer, STAT News, and The Washington Post.

Claudia Kawas, M.D.
University of California, Irvine

Upon completing her medical degree, Dr. Kawas enrolled at Johns Hopkins University for a two-year fellowship in 1985. Upon completing the fellowship, she remained at the institution to study Alzheimer's disease. As a faculty member, she collaborated with epidemiologist Walter Stewart and partook in the Baltimore Longitudinal Study on Aging. In 1997, she co-led a study examining the impact of estrogen on the risk of Alzheimer's disease. Kawas left Johns Hopkins in 2000 to accept a similar faculty appointment at the University of California, Irvine (UC Irvine).

As the Al and Trish Nichols Chair in clinical neurology, Kawas established the Leisure World Cohort Study to monitor the health and well-being of people 90 and older in Laguna Woods, California. In 2012, she was honored as a Visionary Woman for her clinical contributions to Alzheimer's disease research and care by the Orange County Chapter of

the Alzheimer's Association. The following year, the National Institute on Aging renewed its funding for the Leisure World Cohort Study for another five years.

In 2017, Kawas was presented with the Khalid Iqbal, Ph.D., Lifetime Achievement Award in Alzheimer's Disease Research for her "for her numerous contributions to clinical and epidemiological research in Alzheimer's disease, aging and dementia." In the same year, she also received the American Academy of Neurology's Potamkin Prize for dementia research.

C. Dirk Keene, M.D., Ph.D.
University of Washington Medicine

Dr. Keene received his education at the University of Nevada, Las Vegas (B.S. in Cell and Molecular Biology) and the University of Minnesota (M.D. and Ph.D. in Neuroscience). His post-graduate medical training in Anatomic Pathology and Neuropathology was at the University of Washington (UW). Currently, Dr. Keene is the Nancy and Buster Alvord Endowed Chair in Neuropathology, Professor of Laboratory Medicine and Pathology, Adjunct Professor of Ophthalmology and Neurological Surgery, Director of the Neuropathology Division and Fellowship, Associate Director of the UW Alzheimer's Disease Research Center, and Leader of the BioRepository and Integrated Neuropathology (BRaIN) Laboratory. The goal of the BRaIN Laboratory is to facilitate development of diagnostic, therapeutic, and preventative approaches to understand, prevent, and treat brain aging, injury, and neurodegenerative disease by combining traditional and precision neuropathological strategies in human cells and tissues.

Dr. Keene is Board Certified in Anatomic Pathology and Neuropathology, leads multiple neuropathology cores supporting neurodegenerative and traumatic brain injury (TBI) cohort studies, and strives to promote scientific advancement through diagnostic and research neuropathology. Dr. Keene was a member of the first and second consensus meetings on the neuropathology of chronic traumatic encephalopathy, co-chairs the current (and prior) working group to establish neuropathology common data elements for TBI. Dr. Keene strives to adapt existing, and develop novel, technologies to maximize the scientific utility of archived and prospectively acquired human brain tissue, and energetically promotes tissue and data sharing, and facilitation of local and national research, through collaborative and cooperative mechanisms.

David Kleinfeld, Ph.D.
University of California, San Diego

Dr. Kleinfeld received his Ph.D. from UCSD in mid-1984, spent a decade on the research staff of Bell Laboratories, and then joined the faculty at UCSD in late 1995. He is a recipient of a David and Lucile Packard Foundation Interdisciplinary Science Award, a NIH Directors Pioneer Award, a NINDS Research Program Award, currently holds the Dr. George Feher Experimental Biophysics Endowed Chair, and is funded primarily through the NIH BRAIN initiative, where he leads the "Low&High" Team BRAIN Circuits Program. David is a fellow of the American Association for the Advancement of Science and a member of the American Academy of Arts and Sciences. He currently leads the Specialization on Computational Neuroscience through the Neurosciences Graduate Program.

David S. Knopman, M.D.
Mayo Clinic

Dr. Knopman is a clinical neurologist involved in research in late-life cognitive disorders, such as mild cognitive impairment and dementia. His specific interests are in the very early stages of Alzheimer's disease, in cognitive impairment due to stroke (cerebrovascular disease) and in cognitive impairment due to frontotemporal degeneration. He is involved in epidemiology, clinical trials and diagnostic studies of these disorders.

Dr. Knopman's primary role is as a clinician, and he sees patients with various cognitive disorders nearly every day. Goals of his research are, first, to improve diagnostic accuracy and, second, to find better treatments for patients with Alzheimer's disease, frontotemporal degeneration and cerebrovascular cognitive disorders.

In addition, Dr. Knopman served as the chair for the Alzheimer's Association Medical and Scientific Advisory Group, was the former chair for the Medical Advisory Council of the Association for Frontotemporal Degeneration, and served as deputy editor for Neurology from 2009-2016.

Ian Kremer, J.D.
Leaders Engaged on Alzheimer's Disease (LEAD) Coalition

Ian Kremer is the Executive Director for the LEAD Coalition and a nationally recognized public policy expert in Alzheimer's disease and other forms of dementia. Kremer joined the coalition in 2012 as its first Executive Director and has since doubled the membership. The LEAD Coalition has elevated the national discussion by contributing to development of the National Plan to Address Alzheimer's Disease, securing historic increases in funding for dementia research at the National Institutes of Health in collaboration with other stakeholders, and working with the Centers for Medicare and Medicaid Services, the Food & Drug Administration and the Centers for Disease Control & Prevention to improve detection and diagnosis of cognitive impairment.

Kremer participates on several national steering committees, including the "National Research Summit on Care, Services, and Supports for Persons with Dementia and Their Caregivers." He is co-chair of the AD Patient and Caregiver Engagement initiative's governance working group, and a member of the Executive Committee for Dementia Friendly America. Before his work at the LEAD Coalition, Kremer led state and local policy for 15 years at the Alzheimer's Association, National Capital Area chapter.

Kremer earned his undergraduate degree with honors from Washington University in St. Louis and his law degree from the University of Michigan. He is a member of the Virginia State Bar and the American Bar Association.

Melissa Lamar, Ph.D.
Rush University Medical Center

Dr. Lamar is a Professor in the Division of Behavioral Sciences at Rush University Medical Center, and a Clinical Neuropsychologist in the Rush Alzheimer's Disease Center. She received her Ph.D. in Clinical Neuropsychology from Drexel University and completed her postdoctoral training in cognitive neuroscience within the intramural program of the Laboratory of Behavioral Neurosciences at the National Institute on Aging. She worked at the Institute of Psychiatry King's College London and the University of Illinois at Chicago prior to joining the Rush faculty in 2016.

Her research focuses on modifiable risk and resilience factors as they relate to brain aging and cognition with a particular focus on older Latino and African American adults. Dr. Lamar employs novel geospatial and neuroimaging approaches and incorporates digital technology into her work assessing cognitive functioning. The overarching goal of her work is to identify modifiable risk and resilience factors to reduce health disparities and increase

health equity. Dr. Lamar has published extensively, is the PI of several NIH grants, and has received numerous honors and awards for her work including Fellows status of the American Psychological Association and the Arthur Benton Award for Mid-Career Research from the International Neuropsychological Society, as well as from the International Society to Advance Alzheimer's Research and Treatment's Diversity and Disparities Professional Interest Area.

Cristian A. Lasagna-Reeves, Ph.D.
Indiana University

Dr. Lasagna-Reeves is an associate professor of anatomy, cell biology and physiology at the Indiana University School of Medicine, received the prestigious 2024 Rainwater Prize for Innovative Early-Career Scientist at the Alzheimer's Association's Tau2024 Global Conference in March 2024. Dr. lasagna-Reeves was selected because of his exceptional contributions to neurodegenerative disease research, particularly his innovative work in understanding the role of the tau protein in Alzheimer's disease and related dementias.

Born in Chile, Lasagna-Reeves earned his Ph.D. at the University of Texas Medical Branch in Galveston and conducted his postdoctoral training at Baylor College of Medicine in Houston. He opened his lab at IU School of Medicine in 2017.

Lasagna-Reeves also received the Inge Grundke-Iqbal Award for Alzheimer's Research at the 2023 Alzheimer's Association International Conference. A journal article on Bassoon — a protein that serves as scaffolding for tau-seed propagation — published in Nature Neuroscience in 2022 was named the "most impactful study published in Alzheimer's research over the preceding two years."

This research discovered how the Bassoon protein may contribute to the aggregation and spreading of pathological forms of tau and that downregulation of Bassoon could offer new avenues for therapeutic intervention for tauopathies.

Caitlin S. Latimer, M.D., Ph.D.
University of Washington, School of Medicine

Dr. Latimer is a UW acting instructor and clinical specialist in neuropathology, which includes the clinical practice of neurosurgical, neuromuscular, ophthalmic, and autopsy subspecialties, with a particular interest in neurodegenerative disease.

Dr. Latimer is committed to research efforts focused on the role of the synapse in neurodegenerative disease with the goal of understanding the changes that occur at the earliest stages of disease and how these changes differ in individuals without neurodegenerative disease. Dr. Latimer additionally works with neuroimaging experts through the Integrated Brain Imaging Center to bridge the gap between neuroradiology and neuropathology and enhance targeted sampling through the use of neuroimaging data and techniques.

Dr. Latimer's clinical interests include neuro-oncology, neuromuscular disease, neurodegenerative disease, and cerebrovascular disease. Her research interests include brain aging and age-related neurodegenerative processes in the brain and spinal cord with a particular emphasis on Alzheimer's disease and the mechanisms underlying resistance and resilience to neurodegenerative disease.

Edward B. Lee, M.D., Ph.D.
University of Pennsylvania Perelman School of Medicine

Dr. Lee is the associate director of the Penn Alzheimer's Disease Research Center and co-director of the Institute on Aging. He is also an attending physician at the Hospital of the University of Pennsylvania and associate professor in the Department of Pathology and Laboratory Medicine. Dr. Lee is currently principal investigator of the Translational Neuropathology Research Laboratory supporting studies on the molecular neuropathology of Alzheimer's disease, frontotemporal degeneration and amyotrophic lateral sclerosis, recently discovering a novel form of dementia called vacuolar tauopathy. Dr. Lee graduated Phi Beta Kappa and with honors from Stanford (1997) and obtained his M.D.. and Ph.D.. degrees from the University of Pennsylvania (2005) where he studied amyloid pathology in various experimental models under the mentorship of Virginia M.-Y. Lee, Ph.D..

Jin-Moo Lee, M.D., Ph.D.
Washington University in St. Louis, School of Medicine

Dr. Lee is the Andrew B. & Gretchen P. Jones Professor in Neurology and the Chairman Department of Neurology at Washington University School of Medicine. He is the Neurologist-in-Chief at Barnes-Jewish Hospital. He has authored more than 200 research articles, chapters, reviews, and editorials on stroke and Alzheimer's Disease, and the interface of these two diseases found in the elderly. His research spans the translational spectrum from cell and animal models of neurological diseases to clinical studies involving genetics and multimodal neuroimaging. Dr. Lee has been continuously funded by the NIH since 2000.

Dr. Lee has received several awards for research excellence — most recently the Javits Neuroscience Investigator Award (R37 Merit Award). He graduated from Yale College with a degree in Molecular Biophysics and Biochemistry, then attended Weill Cornell Medical College, earning an M.D. and Ph.D. in neuroscience. After completing residency training at the University of Pennsylvania, he completed a neurovascular fellowship at Washington University where he subsequently joined the faculty in the Department of Neurology.

Anne Leonard, MPH, RN
American Heart Association/American Stroke Association

Dr. Leonard is a senior science and medicine advisor for the American Stroke Association (ASA) division of the American Heart Association (AHA). She is the lead for the Stroke Council, Council on Hypertension, and Council on Clinical Cardiology and staffs several science subcommittees within those councils. She has worked in stroke science since 1987, when she worked for the Department of Neurology at the University of Texas Health Science Center at San Antonio on the Stroke Prevention in Atrial Fibrillation study, which was funded by the National Institute of Neurological Disorders and Stroke. During her 20-year tenure with this department, she also coordinated other studies on acute stroke treatment, primary/secondary prevention of stroke, and novel early-phase neuroprotective agents. Her work on these research studies included the roles of study coordinator and sub investigator. She also was involved in quality improvement projects at affiliated hospitals. She worked 5 years of her career with the Department of Neurosurgery, coordinating and executing clinical research trials on intracerebral hemorrhage, including two surgical intervention studies (the Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation study and the Clinical Trial on Treatment of Intraventricular Hemorrhage), as well as an epidemiology study (Ethnic/Racial Variations of Intracerebral Hemorrhage). She served as the interim stroke coordinator in the five-hospital system for a year and consulted with this system thereafter. During those years, she taught residents, medical students, nurses, paramedics, and allied health professionals about stroke. Before leaving

the university, she consulted with the AHA/ASA about its stroke portfolio. She rejoined the AHA/ASA in 2013.

Vijay S. Limaye, Ph.D.
Natural Resources Defense Council

Dr. Limaye is a climate and health scientist in NRDC's Science Office. As an epidemiologist, he is broadly interested in addressing international environmental health challenges—quantifying, communicating, and reducing the risks associated with climate change—with a focus on the public health burdens of air pollution and extreme heat. At NRDC, he leads economic valuation research and advocacy to understand and address the significant health costs of climate change and he works to defend the science that underpins the Clean Air Act. Prior to joining NRDC, he worked as a U.S. Environmental Protection Agency scientist, focusing on Clean Air Act regulatory implementation, air quality monitoring policy, and health risk communication. Limaye, who also speaks Spanish and Hindi, has led multiple research studies on the health impacts of climate change, including analyses of air pollution and extreme heat in both the U.S. and India. He holds a bachelor's degree from the University of California, Berkeley and a Ph.D. in environmental epidemiology from the University of Wisconsin, Madison. He is based out of NRDC's Chicago office.

Jennifer Hagerty Lingler, Ph.D.
University of Pittsburgh, School of Nursing

Since receiving her MA in Bioethics, Dr. Lingler has incorporated attention to ethical concerns in her research and teaching. Her research focuses on provider-patient communication, health behaviors, and late-life cognitive impairment. She is particularly interested in psychosocial and ethical implications of such impairment and challenges of conducting research with those who have mild cognitive impairment or more advanced disease. Dr. Lingler leads the Outreach, Recruitment and Engagement Core at the University of Pittsburgh Alzheimer's Disease Research Center, and studies recruitment innovations to enhance diversity in research on Alzheimer's disease, as well as the impact of disclosing amyloid imaging results to those with mild cognitive impairment.

Dr. Lingler facilitates research apprenticeship experiences and teaches *Responsibilities and Activities of a Scientist* to doctoral students in the School of Nursing. She has also taught ethics in the University's Graduate Certificate Program in Gerontology, and frequently lectures on ethical issues in dementia care, neurological assessment, and the differential diagnosis and management of dementia.

Xiao-Hong Lu, Ph.D.
Louisiana State University

Dr. Lu's research focus on molecular genetics of neuropsychiatric disorders. Trained as a psychiatrist and neuropharmacologist, Dr. Lu completed his postdoctoral training in molecular genetics and was appointed as an Assistant Researcher at the Center for Neurobehavioral Genetics of the University of California, Los Angeles (UCLA). Dr. Lu developed the first BAC transgenic Parkinson's disease (PD) mouse model that recapitulates the cardinal features of PD. His translational study of Huntington's disease (HD) identified a novel therapeutic strategy (Sci. Transl. Med., 2015; Highlighted in Nat Rev Drug Discov. and was selected as the most influential paper of 2015 by HD insight). Dr. Lu co-invented a single-cell transgenic technology (MORF, Mosaicism with Repeat Frameshift) that received support from the first round of the Brain Initiative award. Funded by a NARSAD Young Investigator Award, Lu lab generated the next-generation mouse model for schizophrenia (Mol Psychiatry, 2019). Dr. Lu's lab invented a robust method for efficient and precise CRISPR/Cas9 mediated genome editing in the adult mammalian brain. Dr. Lu is funded by grants from NIEHS, NASA, and NIGMS.

Elizabeth Rose Mayeda, Ph.D.
University of California, Los Angeles

Dr. Mayeda is an Associate Professor in the Department of Epidemiology at the UCLA Fielding School of Public Health. Dr. Mayeda received her BA in Integrative Biology and Public Health from the University of California, Berkeley, her MPH in Epidemiology from the Columbia University Mailman School of Public Health, and her Ph.D. in Epidemiology and Translational Science from the University of California, San Francisco (UCSF). Before joining the faculty at UCLA in 2018, she completed a postdoctoral fellowship at UCSF.

Dr. Mayeda's research focuses on identifying modifiable determinants of cognitive decline and dementia in late life. Her research program has both applied and methodological themes. Her research focuses on describing and identifying mechanisms contributing to disparities in late-life cognitive and brain health. She also leads work addressing methodological challenges in longitudinal studies of cognitive aging and dementia risk. Her long-term research goals are to: (1) identify effective population-level strategies to prevent dementia and promote equity in cognitive and brain aging and (2) develop research tools to strengthen causal inference in dementia research and lifecourse epidemiology.

Dr. Mayeda is recognized as an expert in dementia epidemiology and epidemiologic methods. She gave an NIH Rising Star Invited Lecture in 2019 and received the Society for Epidemiologic Research Brian MacMahon Early Career Award in 2020. She holds multiple national and international professional leadership and service roles related to advancing the application of rigorous quantitative methods in applied research, including serving on the leadership committees of the Methods in Longitudinal Research on Dementia (MELODEM) Initiative and the Advanced Psychometrics Methods in Cognitive Aging Conference.

Ann McKee, M.D.
Boston University

Dr. Mckee, a William Fairfield Warren Distinguished Professor of Neurology and Pathology, is a board-certified neurologist and neuropathologist whose research has significantly advanced scientific understanding of post-traumatic neurodegeneration and chronic traumatic encephalopathy (CTE). Dr. McKee completed her undergraduate studies at the University of Wisconsin and earned her medical degree from the Case Western Reserve University School of Medicine. She completed her residency in neurology at Cleveland Metropolitan General Hospital and her neuropathology training at Massachusetts General Hospital. Additionally, she served as an assistant professor at Harvard Medical School. Currently, she is the Director of the Boston University Alzheimer's Disease Research Center and the Boston University CTE Center.

Her work established that repetitive head impacts—including both concussive and non-concussive impacts experienced by athletes in contact sports, military personnel, and victims of domestic violence—lead to a progressive tauopathy, CTE. Dr. McKee defined the principal neuropathological features necessary for the diagnosis and staging of CTE. Her extensive research, which includes the creation of the world's largest brain bank focused on brain trauma, has been instrumental in recognizing CTE as a major public health concern worldwide.

Dr. McKee has investigated the brains of thousands of athletes, military veterans, and other individuals exposed to repeated brain trauma. Her innovative techniques, such as multiplex immunofluorescence, single-nucleus RNA sequencing, spatial transcriptomics, and fluorescent microscopy with 3D imaging, have demonstrated that repetitive head impacts lead to changes in gene expression, neuroinflammation, vascular injury, blood-brain barrier disruption, and the loss of neurons, white matter, and synapses. She was the first to report the association between ALS and CTE. She reported the first case of CTE in ice hockey, soccer, mixed martial arts, baseball, high school football, and college football. Dr. McKee reported the youngest athlete ever diagnosed with CTE (17 years). Her team defined the roles of other pathological proteins, TDP-43, beta-amyloid, and alpha-synuclein, in the development and progression of CTE. Throughout her career, Dr. McKee

has consistently raised awareness about the safety risks associated with CTE, particularly for athletes in contact sports and military veterans exposed to repetitive head trauma and blast injuries.

Through her work with the Boston University Alzheimer's Disease Research Center and the Framingham Heart Study, Dr. McKee also helped define microvascular injury and the neuropathology of aging and Alzheimer's disease.

Jason Meyer, Ph.D.
Indiana University School of Medicine

Dr. Meyer received his bachelor's degree from Colgate University and his doctoral degree from the University of Missouri. He completed his postdoctoral training at the University of Wisconsin and was later promoted to the rank of assistant scientist, where he developed the foundational ability to differentiate human pluripotent stem cells into retinal neurons. He is currently an Associate Professor of Medical and Molecular Genetics at Indiana University School of Medicine and a Primary Investigator at the Stark Neurosciences Research Institute, with adjunct appointments in Pharmacology and Toxicology, as well as Ophthalmology. His research focuses upon the use of human pluripotent stem cells as in vitro model of neurodegeneration, including iPS cell reprogramming as well as Crispr/Cas9 gene editing. Ongoing projects in his lab explore the use of these cells for studies of neurodegeneration associated with either glaucoma or Alzheimer's disease, as well as neuron/glia interactions and how glial cells such as astrocytes and microglia mediate neurodegeneration of neurons.

Joelle Millikin, M.D.
Aspirus Rhinelander Hospital

As a double-board-certified internal and geriatric medicine doctor, Dr. Joelle Millikin offers exceptional care and guidance to her patients and their care partners. Her expertise includes chronic disease prevention and care, including lifestyle intervention, medical counseling, and medication management. Dr. Millikin also has extensive experience in memory care.

As a graduate of the University of Minnesota in Minneapolis, Dr. Millikin completed her Doctor of Medicine degree at Chicago Medical School at Rosalind Franklin University of Medicine and Science in Illinois. Dr. Millikin then completed her internship and residency in internal medicine at Providence St. Vincent Medical Center in Portland, Oregon. She later completed advanced specialty training in geriatric medicine through her fellowship at Oregon Health & Science University in Portland.

Dr. Millikin enjoys getting to know her patients through their history and physical exams as well as counseling on their diagnosis and working with them on developing a plan for treatment that is realistic for their life and goals of care.

Thomas Montine, M.D., Ph.D.
Stanford University

Dr. Montine received his education at Columbia University (BA), the University of Rochester (Ph.D.), and McGill University (M.D. and CM). His postgraduate medical training was at Duke University, and he was junior faculty at Vanderbilt University where he was awarded the Thorne Professorship in Pathology. In 2002, Dr. Montine was appointed as the Alvord Endowed Professor in Neuropathology and Director of the Division of Neuropathology at the University of Washington. He was Director of the University of Washington ADRC, one of the original 10 Centers in the US, and passed that responsibility to able colleagues. In 2010, Dr. Montine was appointed Chair of the Department of Pathology at the University of Washington. In 2016, Dr. Montine was appointed Chair of the Department of Pathology at Stanford University where he is the Stanford Medicine Endowed Professor in Pathology.

Dr. Montine is the founding Director of the Pacific Udall Center, one of 9 NINDS-funded Morris K. Udall Centers of Excellence for Parkinson's Disease Research. The center performs basic, translational, and clinical research focused on cognitive impairment in Parkinson's disease. The Montine Laboratory focuses on the structural and molecular bases of cognitive impairment with the goal of defining key pathogenic steps and thereby new therapeutic targets. Dr. Montine was the 2015 President of the American Association of Neuropathologists and led/co-led recent NIH initiatives to revise diagnostic guidelines for Alzheimer's disease (NIA), develop research priorities for the National Alzheimer's Plan (NINDS and NIA), and develop research priorities for Parkinson's Disease (NINDS).

Elizabeth Mormino, M.D.
Stanford University

Dr. Mormino completed a Ph.D. in Neuroscience at UC Berkeley in the laboratory of Dr. William Jagust, where she performed some of the initial studies applying Amyloid PET with the tracer PIB to clinically normal older individuals. This initial work provided evidence that the pathophysiological processes of Alzheimer's disease begin years before clinical symptoms and are associated with subtle changes to brain regions critical for memory. During her postdoctoral fellowship with Drs. Reisa Sperling and Keith Johnson at Massachusetts General Hospital she used multimodal imaging techniques to understand longitudinal cognitive changes among individuals classified as preclinical AD. In 2017, Dr. Mormino joined the faculty at Stanford University in the department of Neurology and Neurological Sciences. Her research program focuses on combining imaging and genetics to predict cognitive trajectories over time, and the integration of novel PET scans to better understand human aging and neurodegenerative diseases.

Amy R. Nelson, Ph.D.
University of South Alabama

Dr. Nelson is currently an Assistant Professor at Frederick P. Whiddon College of Medicine, University of South Alabama. She received her Ph.D. in Neuroscience from the University of Alabama at Birmingham in 2013. In the currently funded R00, the Nelson lab is investigating whether Alzheimer's disease (AD) amyloid-beta causes brain pericytes to contract, reducing cerebral blood flow and compromising blood-brain barrier (BBB) integrity, is worsened in normal aging and is dependent on the p75NTR pathway. Also, we are investigating causes of pericyte degeneration and blood-brain barrier dysfunction in AD and are particularly interested in post-translational modifications and expression level changes of key receptors at the BBB. The ultimate goal is to discover new therapeutic targets for neurodegeneration by preventing and/or repairing BBB disruption.



Peter Nelson, M.D., Ph.D.
University of Kentucky, College of Medicine

Dr. Nelson is a clinically active experimental neuropathologist and leader of the University of Kentucky Alzheimer's Disease Research Center Neuropathology Core, and its world-class biobank. Peter's Ph.D. work was in Dr. Clif Saper's lab focused on an animal model of tau neurofibrillary pathology – tau tangles in aged sheep brains. Following medical school, residency, and neuropathology fellowship, Peter was trained by Dr. John Trojanowski and Zissimos Mourelatos at University of Pennsylvania (where he did residency, fellowship, and post-doc). Peter's work at the University of Kentucky has provided insights about studying the associative impact of pathology in the aged brain, and how genetics may play a role in neurodegenerative diseases. Most of his >200 published studies have related to human diseases because many of the phenomena we see in aged persons' brains are unique to that milieu as far as we know. The impact of mixed pathologies is a recurrent theme in Peter's work. Peter contributed to key papers on newly recognized (as well as well-known) pathologies -- primary age-related tauopathy (PART), Lewy body diseases, age-related tau astrogliopathy (ARTAG), limbic-predominant age-related TDP-43 encephalopathy (LATE), and brain arteriolosclerosis -- as well as participating in consensus papers on the neuropathologic diagnosis of Alzheimer's disease itself.

Huong Q. Nguyen, Ph.D., RN
Kaiser Permanente

Dr. Huong Nguyen is a nurse and health services researcher whose work is broadly focused on the care of older adults with chronic and serious illnesses. She is currently serving as interim director of the Division of Health Services Research & Implementation for the Department of Research & Evaluation. She is also a professor in the Department of Health Systems Science of the Kaiser Permanente Bernard J. Tyson School of Medicine.

Dr. Nguyen conducts ongoing partnered research with operational and clinical leaders in Kaiser Permanente Southern California. She uses observational and experimental methods to improve care processes and outcomes for older adults with multiple chronic conditions across the illness trajectory and care continuum. Her current research and evaluation efforts are focused on patient and family-centered, home and community models of geriatric-palliative care, to optimize the health and well-being of older adults and their family caregivers.

Andre Obenaus, Ph.D.
University of California, Riverside

Dr. Obenaus receive a Ph.D. in Neurophysiology from the University of British Columbia, Vancouver, B.C. in 1989. He has a long-standing interest in the use of non-invasive imaging modalities to understand normal brain physiological functions and those that accompany pathophysiology. Probing white matter using neuroimaging methods is an area of published interest using diffusion tensor imaging (DTI) as a non-invasive readout. Dr. Obenaus has published several studies in altered white matter after mild TBI (Wendel 2018) and in our proposed limited bedding and nesting (LBN) model of fragmented maternal care (Bolton et al 2018). These approaches used tractography as well as quantitative indices of white matter alterations including dispersion. He also has experience in acquiring resting and evoked fMRI data using very light planes of anesthesia.

In addition, as a co-investigator in the NIMH funded "Conte Center on Brain Programing in Adolescent Vulnerabilities" he has been examining developing new methods including gray-matter DTI to assess local brain changes as well as long-range circuits in rodents exposed to early life adversity (Molet 2016, Bolton 2018). He has described altered hippocampal microstructure using DTI that reflected behavioral alterations including memory deficits and anhedonia. Dr. Obenaus's recent report in Biological Psychiatry reported increased tracts in adults experiencing fragmented early-life experiences (Bolton et al 2018). These novel and other emerging analytical approaches will be utilized in proposed research efforts related to understanding modifications to brain circuitry.

As the former Director of the Non-Invasive Imaging Laboratory (NIL) at Loma Linda University, he was instrumental in purchase, installation and all imaging activities on our high field MRIs (4.7T, 11.7T), a micro-CT and a micro-PET which supported the research efforts of numerous NASA, DOD and NIH funded researchers as well as my own research. Currently, Dr. Obenaus serves as the Director of the Preclinical and Translational Imaging Center at UCI which houses a state of the art 9.4T MRI. He has extensive experience as well as significant resources for computational analysis of imaging data and examples of these efforts are reported in Ghosh et al 2012 and Donovan et al 2012, including national and international patents. These experiences, coupled with his productive collaborations with the PI, TZ Baram for close to ten years, provide him with the skills and the passion to enable the success of our renewed Center.

Ozioma Okonkwo, Ph.D.
University of Wisconsin-Madison School of Medicine and Public Health

Dr. Okonkwo is an Associate Professor in the Department of Medicine and the Alzheimer's Disease Research Center at the University of Wisconsin-Madison. Dr. Okonkwo's research focuses on clarifying how alterations in the brain and other biomolecules (such as cerebrospinal fluid ß-amyloid) place some cognitively normal individuals on a trajectory that culminates in probable Alzheimer's disease. In this context, his lab is also concerned with discovering new knowledge regarding the modulation of the link between brain changes and cognitive decline by both modifiable (e.g., physical exercise, cognitively stimulating activities) and non-modifiable (e.g., genetic makeup) factors.

Monique Pappadis, MEd, Ph.D.
University of Texas, Medical Branch

Dr. Pappadis is a tenured Associate Professor and Vice Chair in the Department of Population Health and Health Disparities at the University of Texas Medical Branch (UTMB) at Galveston. She is a Fellow of the Sealy Center on Aging, and currently the Accessing Underserved Populations Lead for the Institute for Translational Sciences. Dr. Pappadis is also an Investigator and the Director of Dissemination and Cultural Humility at TIRR Memorial Hermann's Brain Injury Research Center in Houston, Texas.

Her research aims to advance health equity and decrease ethnic minority health disparities, particularly among persons with traumatic brain injury (TBI) or stroke, as well as improve care transitions and continuity of care following acute and post-acute care. Her recent work aims to improve screening for elder mistreatment with emphasis on vulnerable, older adults with mild cognitive impairment or Alzheimer's Disease and Related Dementias, as well as the intersection between elder mistreatment and TBI. She has a continued interest in minority aging, gender/sex disparities in rehabilitation, health literacy of patients and caregivers, and psychosocial adjustment to disability. She serves on a number of national committees and working groups, such as the American Congress of Rehabilitation Medicine, the Academy of Certified Brain Injury Specialists (ACBIS) of the Brain Injury Association of America (BIAA), Pink Concussions, the Moody-Galveston Brain Injury Conference - Social and Health Disparities, the National Institute of Neurological Disorder and Stroke (NINDS), and the National Academies of Sciences, Engineering, and

Medicine (NASEM). She is recognized nationally for her professional service, contributions to the medical rehabilitation field, and mentorship of scholars in the US and abroad.

Henry L. Paulson, M.D., Ph.D.
University of Michigan, Ann Arbor

Dr. Paulson is the Lucile Groff Professor of Neurology in the Department of Neurology at the University of Michigan, where he also serves as Director of the Michigan Alzheimer's Disease Center. Dr. Paulson received his M.D. and Ph.D. degrees from Yale University, completed residency and fellowship training at the University of Pennsylvania, and previously taught at the University of Iowa. His research and clinical interests concern the causes and treatment of age-related neurodegenerative diseases, with an emphasis on repeat expansion diseases and age-related dementias. He is a member of the National Academy of Medicine, an elected fellow of the American Association for the Advancement of Science, and a recipient of the Landis Outstanding Mentor Award from the National Institutes of Health.

Leonard Petrucelli, Ph.D.
Mayo Clinic

Dr. Petrucelli is a consultant and chair of the Department of Neuroscience at Mayo Clinic in Florida. He holds the academic rank of professor of neuroscience and has full faculty privileges in molecular neuroscience at Mayo Graduate School. He is recognized as the Ralph B. and Ruth K. Abrams Professor. Dr. Petrucelli earned his Bachelor of Science degree at Barry University, Miami, and his Ph.D. degree in molecular and cellular biochemistry at Loyola University and Stritch School of Medicine, Chicago. He came to Mayo Clinic's Florida campus as a research fellow in 2000 and joined the neurosciences research staff two years later.

Dr. Petrucelli and his research team are at the forefront of their field, researching the cellular mechanisms that cause neurodegeneration in Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, and frontotemporal dementia (FTD). By combining expertise in drug discovery, cell biology and induced pluripotent stem cell (iPSC) modeling, his lab aims to develop therapies for the treatment of diseases characterized by abnormal protein aggregation. Dr. Petrucelli's team recently discovered a new therapeutic target and biomarker with the aim of improving the diagnosis and prognosis for patients suffering from FTD and ALS. His team's research has been published in top tier journals including Science, Nature Medicine, Nature Neuroscience, Neuron, Journal of Clinical Investigation and Annals of Neurology. Dr. Petrucelli is principal investigator for several grants funded by the National Institutes of Health (NIH) including

R35 and is director of two funded NIH programs focused on c9orf72 and tau. He serves on the Scientific Advisory Board of Science Translational Medicine. He is also the Chief Scientific Advisor to Target ALS Foundation. Lastly, he was recently appointed as vice- chair to the Florida Alzheimer's Disease Research Grant Advisory Board.

Mary Jo Pugh, Ph.D., RN
University of Utah, School of Medicine

Dr. Pugh developed a research program to examine the long-term sequelae and outcomes of military exposures which integrated her training as a Veteran, a nurse, and a developmental psychologist. Over the past decade she has targeted her work using VA data to identify phenotypes in populations with complex comorbidity such as those with traumatic brain injury (TBI) and complex multi-symptom illness. Dr. Pugh's current work related to TBI includes longitudinal observational and prospective studies to identify the emergence of distinct neurodegenerative conditions such as cognitive impairment, dementia, epilepsy, and clusters of multimorbidity that may have similar or networked biological underpinnings. The longitudinal observational studies of approximately 2.5 million Veterans currently link Department of Defense (DoD) combat theatre and health system data with VA health system data and will further link with DoD serum repository data. These studies aim to understand which individuals are at highest risk of dementia, other neurodegenerative diseases, mental health conditions, and deficits in functional outcomes after mild TBI. They also investigate the possibility of using personalized medicine to address treatment choices by using deep learning models to identify optimal treatment pathways for specific phenotypes to inform treatment guidelines for mild TBI in the context of multimorbidity.



Yakeel T. Quiroz, Ph.D.
Massachusetts General Hospital at Harvard Medical School

Dr. Quiroz is Associate Professor in the Departments of Psychiatry and Neurology at Massachusetts General Hospital and Harvard Medical School in Boston, MA. She is the Director of the Mass General Familial Dementia Neuroimaging Lab, and the Multicultural Alzheimer's Prevention Program-MAPP.

Her research interests include brain imaging and genomics, and early detection and prevention of Alzheimer's disease and other dementias. Research in her lab is focused on the study of cognitive and brain changes that predispose individuals to develop dementia later in life. She is currently the principal investigator of the Colombia-Boston (COLBOS) longitudinal biomarker study on early-onset autosomal dominant Alzheimer's disease, and the Boston Latino Aging Study (BLAST).

Dr. Quiroz has published over 100 peer-reviewed articles, and her work is recognized by her peers at the local, national and international level. She has earned several awards throughout her career, including an NIH Director's Pioneer Early Independence Award, the FABBS Foundation Early Career Impact Award, and the Alzheimer's Association Inge Grundke-Iqbal Award for Alzheimer's Research.

Gil Rabinovici, M.D.
University of California, San Francisco

Dr. Gil Rabinovici holds the Edward and Pearl Fein Distinguished Professorship in Memory & Aging in the UCSF Department of Neurology. He received his BS degree from Stanford University and M.D. from Northwestern University Medical School. He completed his neurology residency (and chief residency) at UCSF and a behavioral neurology fellowship at the UCSF Memory and Aging Center (MAC), where he cares for patients with cognitive disorders.

Dr. Rabinovici's research investigates how structural, functional, and molecular brain imaging techniques can be used to improve diagnostic accuracy in dementia and study the biology of neurodegenerative diseases, with the goal of accelerating drug development. He is the director of the NIH-funded UCSF Alzheimer's Disease Research Center, study chair of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) and New IDEAS studies (~25,000 total participants), as well as co-PI on the emerging Alzheimer's Network for Treatment and Diagnostics (ALZ-NET), co-PI of the Longitudinal Evaluation of Alzheimer's Disease Study (LEADS), ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI), DIAGNOSE CTE Project-II, and PI on several additional national and local

clinical, imaging and translational studies focused on Alzheimer's disease and related disorders. His work is supported by the NIH, Alzheimer's Association, American College of Radiology, Rainwater Charitable Foundation, and industry partners. He has authored over 350 peer-reviewed publications, and the impact of his work is ranked in the top 1% in the field of Neuroscience.

Dr. Rabinovici's contributions have been recognized with numerous awards, including the 2025 Potamkin Prize for Research in Pick's, Alzheimer's, and Related Disease from the American Academy of Neurology (AAN) and the American Brain Foundation, 2022 Kuhl-Lassen Award from the Society for Nuclear Medicine and Molecular Imaging, the 2015 Christopher Clark Award in Amyloid Imaging, the 2012 AAN Research Award in Geriatric Neurology, and the 2010 de Leon Prize from the Alzheimer's Association.

Rosa Rademakers, Ph.D.
University of Antwerp, Belgium

Dr. Rademakers received her BSc degree in Biology in 1997 and MSc degree in Biochemistry in 1999 from the University of Antwerp, Belgium. In 2004, she received a Ph.D. degree from the University of Antwerp where she continued her postdoctoral studies before moving to the Mayo Clinic in Jacksonville, Florida in 2005. Since 2007 she was a faculty member at the Neuroscience Department of the Mayo Clinic Jacksonville, Florida, USA, where she became full Professor in 2014. As of 2019, Dr. Rademakers returned to Belgium where she is currently Scientific Director of the VIB-UA Center for Molecular Neurology and full Professor in the Department of Biomedical Sciences at the University of Antwerp.

Dr. Rademakers leads world-wide consortia to identify causal genes and genetic risk factors for two important pathological subtypes of FTD. She combines genomic, transcriptomic, epigenomic and proteomic analyses on unique collections of patients' brain tissues to identify genes and pathways implicated in disease. She also leads a consortium focused on genetic disease modifiers in FTD patients which are known to carry known causal mutations with the goal to identify factors that could explain the large variability in symptom onset, clinical phenotype and disease penetrance in patients with these mutations.

Dr. Rademakers has published over 400 peer-reviewed original articles and reviews. For her work, she has received the Paolo Gontijo Medicine Award and the Sheila Essey Award for ALS Research from the ALS Association in partnership with the American Academy of Neurology. She is also the recipient of the 2016 Potamkin Prize for Research in Pick's, Alzheimer's and Related Disorders of the American Academy of Neurology.

Laura P. W. Ranum, Ph.D.
University of Florida, College of Medicine

Dr. Ranum began her research career in human molecular genetics in 1989 at the University of Minnesota and is currently the Founding Director of the Center for NeuroGenetics and Professor of Molecular Genetics and Microbiology at the University of Florida. Over the past 25 years her laboratory has identified the mutations for a number of neurological disorders including spinocerebellar ataxia types 5 and 8 (SCA5, SCA8), and myotonic dystrophy type 2 (DM2). Her laboratory has developed and uses mouse models to understand how these and other mutations cause disease. Most recently, the Ranum lab created a mouse model of the C9orf72 ALS/dementia mutation that has generated wide interest in the scientific community studying ALS.

A common feature of several of these diseases is that they are caused by genetic mutations in which letters of the genetic code (e.g. CAG or CTG or CCTG) are repeated too many times. Over the years, work on SCA8 in the Ranum lab has led to two discoveries that have changed our understanding of how these microsatellite expansion mutations are expressed. First, they demonstrated that expansion mutations can be expressed in two directions. This means there are often two genes to worry about instead of one (Moseley et al., 2006). More recently, they discovered that a cellular traffic light that scientists thought provided a critical signal required for cells to make proteins does not apply to expansion mutations. These mutations cause the protein-making machinery of the cell to run molecular "red lights," producing up to six unexpected proteins that can accumulate in the brains of patients. The technical name for these proteins is Repeat-Associated Non-ATG, or RAN, proteins (Zu et al., 2011). These discoveries have taught us basic lessons about how genes work and have paved the way for similar discoveries in other diseases. Bidirectional gene expression and RAN proteins are now thought to play a role in more common diseases, including ALS and dementia.

Mollie A. Richards, OT, MS. Ed.

Mollie earned her Bachelor of Science degree in Occupational Therapy from Indiana University School of Medicine and a Master of Science degree in Adult Education from Syracuse University. Her career began in Pittsburgh where she worked as an Occupational therapist with patients with spinal cord injuries, strokes, multiple sclerosis, traumatic head injuries, visual challenges and several other neurological conditions. Her career continued in New York, where she worked as an occupational therapist at several medical rehabilitation and skilled nursing facilities on the east coast.

Mollie is a retired Director of Rehabilitation programs at Jewish Senior Life in Rochester New York, and the Memory Care Service Line Manager. She has extensive experiences in rehabilitation management, program development and led workshops and seminars on topics like Alzheimer's disease for decades.

She was appointed by the governor of New York state to the Coordinating Council for Services Related to Alzheimer's disease and other related Dementia. She was also named the Professional of The Year by the New York Association of Homes and Services for the Aging. She served as Vice Chair, Board of Directors, of the Rochester/Finger Lakes Chapter of the Alzheimer's Association.

Mollie currently serves as a Community Educator and is a past member of the Board of Directors of the Alzheimer's Association, Greater Indiana Chapter. She also serves on the Community Advisory Board of Indiana Alzheimer's Disease Research Center of Indiana University School of Medicine and is a founding member. Mollie worked on the Alzheimer's Associations FY23–25 Diversity, Equity and Inclusion subcommittee Strategic Planning group. Mollie has co-authored several publications and abstracts related to Alzheimer's disease and diversity.

Ralph Richards, BS/RT, MR

Ralph Richards is a long-time community leader and a decorated combat Navy medical corpsman serving with the 3rd Marine Division, Republic of South Vietnam. He was employed with the Eastman Kodak Company, Health Imaging, for 31 years, retiring as Vice-President/Regional Manager.

Ralph, IADRC Community Advisory Board Co-Chair, previously served on the Board of Directors for the Alzheimer's Association of Greater Finger Lakes Chapter. He relocated to Indiana in 2014, where he co-founded the National Institute on Aging (NIA) designated Indiana Alzheimer's Disease Research Center (IADRC) Community Advisory Board (CAB). Ralph has collaborated with the NIA-designated

IADRC faculty and investigators on multiple research grants, including AD-REACH, an IADRC supplement to identify motivators and barriers to participation of community members at risk in Alzheimer's biomarker research.

Over the years Ralph has received multiple awards as a community educator in Alzheimer's neurodegenerative diseases—including the prestigious statewide 2021 Golden Hoosier Award, the 2021 Indianapolis Business Journal Healthcare Heroes Award, in addition to the 2023 American Association for Geriatric Psychiatry, Dr. Iqbal "Ike" Diversity Award for work in research with the Community Advisory Boards, Indiana University School of Medicine at the Indiana Alzheimer's Disease Research Center. He has currently been appointed to the planning board for CLARITiI and is a contributing consultant for the University of California, Davis, Team working with "The Good Life" project for healthy brain and body associated with our military veterans.

He is the past Board of Directors member for the Alzheimer's Association Indiana Chapter. He holds a Bachelor of Science Degree in Radiology Business Management from The George Washington University School of Medicine and Health Sciences in Washing ton, DC and an advanced Bachelor of Science Degree in Professional Studies, Magnetic Resonance Imaging, MR, from Upstate University, School of Health Professionals in Syracuse, New York.

Christine Ritchie, M.D., MPH
Massachusetts General Hospital at Harvard Medical School

Dr. Christine Ritchie is the Minaker Chair in Geriatrics and Director of Research for the Division of Palliative Care and Geriatric Medicine at Massachusetts General Hospital (MGH). At MGH, she is also working to establish the Center for Aging and Serious Illness at the Mongan Institute. Prior to joining MGH, Dr. Ritchie was the Harris Fishbon Distinguished Professor in Clinical Translational Research and Aging in the Division of Geriatrics, Department of Medicine at the University of California San Francisco (UCSF). Dr. Ritchie is a board-certified geriatrician and palliative care physician with long-standing experience in clinical care delivery and advanced illness research. With Dr. Bruce Leff, Dr. Ritchie co-leads the National Home-based Primary Care Learning Network, where they are seeking to improve care for homebound older adults through research, quality improvement and policy initiatives. Dr. Ritchie served as medical director of Clinical Programs in the UCSF Office of Population Health and Accountable Care. She is also an inaugural member of the NIH-funded national Palliative Care Research Cooperative. She is an Associate Editor for the Journal of Palliative Medicine, serves on the Editorial Board of the Journal of Gerontology: Medical Sciences, and is on the Board of the American Academy of Hospice and Palliative Medicine.

Deidre L. Robokos

Family advocate – Mother was diagnosed with LATE in 2024

Deidre is a Partner in Kiernan Trebach LLC's Washington, DC office and is based out of New York City. She practices in the areas of medical and professional malpractice defense. She has defended medical malpractice litigation matters in the state and federal courts throughout Maryland, the District of Columbia, and New York. She previously worked at an insurance defense firm both in New York City and the District of Columbia representing individual and corporate healthcare providers in medical malpractice and professional malpractice cases. Deidre successfully litigated numerous medical malpractice cases as second chair in both state and federal courts in Maryland and the District of Columbia. She obtained the dismissals of several cases through dispositive motions and negotiated voluntary dismissals.

After law school, Deidre began her career as an Assistant Corporation Counsel in the New York City Law Department, Brooklyn Tort Division, where she became a pre-trial Part Leader supervising the attorneys in a pre-trial Part in New York Supreme Court. Deidre represented the various New York City agencies in civil tort lawsuits and litigated cases in New York Supreme and Civil Courts.

Natalia S. Rost, M.D., MPH

Massachusetts General Hospital at Harvard Medical School

Dr. Rost is Chief of the Stroke Division at the Massachusetts General Hospital Department of Neurology and Professor of Neurology at Harvard Medical School. A cum laude graduate of Boston University School of Medicine, she also holds a Master's degree from Harvard School of Public Health. Dr. Rost completed her training at Massachusetts General Hospital and Brigham and Women's Hospital. Dr. Rost is internationally recognized for her expertise in vascular neurology, neuroimaging of cerebrovascular disease, and big-data science applications to personalized clinical outcome prediction in acute stroke. A clinician scientist at the helm of an ambitious research program dedicated to reducing global burden of stroke-related cognitive and functional disability, Dr. Rost is currently the MGH Research Scholar and Principal Investigator of DISCOVERY (discoverystudy.org), an innovative national clinical research network funded jointly by the NINDS/NIA to address post-stroke cognitive impairment and dementia in diverse US populations. Dr. Rost is the author of numerous peer-reviewed publications, book chapters, and co-author of the MGH Handbook of Neurology. She is the recipient of the

2012 Michael S. Pessin Stroke Leadership Award from the American Academy of Neurology and 2017 MGH Neurology Department's Ray Adams Clinical Mentor Award. She is a Fellow of the American Academy of Neurology and American Heart Association, and she serves as Associate Editor of the journal Stroke, Chair of the AAN's Science Committee, and Vice Chair of the AAN's Committee on Public Engagement. Dr. Rost is the Scientific Chair of the 2022 NINDS Alzheimer's Disease-Related Dementias Summit.

Anja Schneider, M.D.
German Research Center of Neurodegenerative Diseases (DZNE)

Dr. Schneider is a psychiatrist specializing in neurodegenerative dementia. She received her M.D. from Hamburg University, Germany and completed her residency at Tübingen and Göttingen University Medical Centers. She is a full professor of clinical dementia research at Bonn University and Chair of the Department of Neurodegenerative Diseases and Geriatric Psychiatry at Bonn University Hospital as well as senior group leader in translational dementia research at the German Research Center of Neurodegenerative Diseases (DZNE) in Bonn. Her lab focuses on the pathological mechanisms of neurodegenerative diseases, in particular the role of extracellular vesicles in propagation of disease pathology. Her recent studies show, that extracellular vesicles derived from oligodendroglia protect neurons from oxidative damage, and may thus be important in neurodegenerative diseases. Another line of research in her lab is the development of fluid biomarkers in Alzheimer's and Parkinson's disease. Dr. Schneider also performs clinical research including intervention trials in Alzheimer's disease and she is PI of the DZNE multicenter, longitudinal cohort DESCRIBE FTD.

Dr. Schneider has received several awards and honors for her work, including among others the German Mental Health Association's Price for Therapeutic Research, a Heisenberg Fellowship from the German Research Foundation and the German Alzheimer's Hirnliga's Steinberg-Krupp Prize.

Julie A. Schneider, M.D., MS
Rush University Medical Center

Dr. Schneider is The Deborah R. And Edgar D. Jannotta Presidential Professor of Pathology and Neurological Sciences, and Associate Director at the Rush Alzheimer's Disease Center (RushADC), at Rush University Medical Center. She completed her Neurology residency at the University of Chicago and Neuropathology fellowship at Emory University and is board certified in both.
Dr. Schneider is also certified in Geriatric Neurology, and has a Master's Degree in Clinical Research (Epidemiology focus). She is the Associate Director and Neuropathology Core Leader of the RushADC; and the senior neuropathologist for multiple studies including the Rush Religious Orders Study, Memory and Aging Project, Minority Aging Research Study, Latino Core, and National Cell Repository for Alzheimer's disease.

Dr. Schneider has provided peer review for over 20 journals; is on several editorial boards and has provided grant reviews for the NIH and other agencies. She has served on numerous advisory boards; and has given lectures, nationally and internationally.
Dr. Schneider has extensive experience with clinical-pathologic epidemiologic studies of aging and dementia and has over 380 peer-reviewed publications and 5 book chapters. She also has extensive experience collaborating, participating in multicenter grants and initiatives, and partnerships with industry to advance science. Dr. Schneider's research explores pathologic factors in age-related cognitive decline, with a focus on vascular, TDP-43, and hippocampal sclerosis, and mixed pathologies in Alzheimer's dementias. Her current research leverages neuropathology to advance risk factor discovery, biomarker development, and prevention strategies for Alzheimer's and related dementias.

Azizi A. Seixas, Ph.D.
Miami University, Miller School of Medicine

Dr. Seixas is Interim Inaugural Chair of the Department of Informatics and Health Data Science at the University of Miami Miller School of Medicine. He is also Founding Director of The Media and Innovation Lab (The MIL), Associate Director of the Center for Translational Sleep and Circadian Sciences (TSCS) and Director of Population Health Informatics in the Institute for Data Science and Computing. He was recently awarded one of Miami's Most Influential and Powerful Black Business Leaders, an Education Champion Awardee by Amazon Web Services for his innovative work using cloud computing technology and his advocacy for improving education and has been recognized by Cell Press as one of the top 100 most inspiring Black scientists in America.

Dr. Seixas has over 175 high impact peer-reviewed publications, book chapters and conference presentations and his work appears in several media-outlets such as CBS, CNN, NBC, Associated Press, The Guardian, Huffington Post, and is the sleep expert for NBC Health News. He is currently the Chair for the American Academy of Sleep Medicine (AASM) Sleep Medicine Disruptors Conference and Change Agents program, Vice Chair of the AASM Artificial Intelligence and Machine Learning sub-committee, the Director of Early Career Faculty Development for NYU Langone Health's Department of Population Health, member of the American Heart Association's Cardiac Rehab Advisory Group, permanent member of the NIH's MESH Study Review Panel, and former Chair of AASM's Young Investigator Research Forum.

Sudha Seshadri, M.D.
UT Health, San Antonio

Dr. Seshadri is a board-certified neurologist, the Robert R. Barker Distinguished University Professor of Neurology, Psychiatry and Cellular and Integrative Physiology at the University of Texas Health Sciences Center at San Antonio where she serves as Founding Director the Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases and of the NIA Designated Alzheimer Disease Research Center (ADRC). She is also an adjunct Professor of Neurology at Boston University and a Senior Investigator at the Framingham Heart Study where she leads studies on blood and sensorimotor biomarkers, MRI and PET imaging. She is a fellow of the American Academy of Neurology and American Neurological Association and has been elected to the American Academy of Physicians.

Her research interests are in using clinical, epidemiological and genomic and multi-omic approaches to identify the biology underlying healthy brain aging, stroke, VCID and ADRD and to study possible preventive and therapeutic interventions. She has obtained over $50M in NIH grant funding, has over 400 publications and has mentored over 40 clinician scientists. She leads neurology working groups within several international consortia such as the CHARGE consortium. She is a PI in markVCID, DIVERSE-VCID and serves on the Steering Committee of the DISCOVERY and CADASIL consortia. She is actively studying the long-term risk of ADRD and neuropsychiatric consequences of COVID-19 infection; she leads the 10 | Page neuropsychiatry task force in the RECOVER initiative and is studying ultrahigh field brain MRI in older adults through a grant funded effort.

Meg Smith, J.D.
Cure Alzheimer's Fund

Meg Smith is the Chief Executive Officer of Cure Alzheimer's Fund, a non-profit organization dedicated to funding research with the highest probability of preventing, slowing or reversing Alzheimer's disease.

Meg was appointed CEO in 2023 after eight years of successfully advancing the research program at Cure Alzheimer's Fund. Through her stewardship, the fund awarded more than $138 million in research grants to scientists and institutions worldwide, representing a substantial portion of the total distributions since the organization's inception in 2004. Meg spearheaded unprecedented year-over-year growth while simultaneously ensuring that CureAlz sustained its model of high-rigor, high-accountability scientific decision making by its external community of leading researchers.

Trained as an attorney and with expertise in business consulting, Meg brings a unique and pragmatic perspective to the organization. She has earned widespread respect within the research community for her collaborative strategy, dynamic vision and impressive mastery of the science.

Prior to her role as Executive Vice President, Research Management, for Cure Alzheimer's Fund, Meg was a consultant with McKinsey & Company and a law clerk for the Massachusetts Supreme Judicial Court. Additionally, she has served as a Fellow at The Berkman (now Berkman Klein) Center for Internet & Society at Harvard University. Meg earned a Juris Doctor degree from Harvard Law School and a Bachelor of Science degree from Duke University.

Heather Snyder, Ph.D.
Alzheimer's Association

Dr. Snyder is the VP of Medical and Scientific Relations at the Alzheimer's Association. She oversees Association initiatives that accelerate Alzheimer's research and provide opportunities for the global dementia community. She is responsible for overseeing the progress the Association has made in Alzheimer's and dementia research funding. She leads the Association's International Research Grant Program and strategic funding initiatives, through which the Association funds investigations that advance understanding of Alzheimer's and moves the field toward solutions for the global Alzheimer's crisis. As the world's largest nonprofit funder of Alzheimer's research, the Association is currently investing over $300 million in more than 920 active best-of-field projects in 45 countries.

Farzaneh A. Sorond, M.D., Ph.D.
Northwestern University Feinberg School of Medicine

Dr. Farzaneh Sorond received her BS in Biochemistry and Biophysics at the University of Houston before earning her M.D. and Ph.D. at Baylor College of Medicine. After a residency at Harvard-Longwood, Dr. Sorond completed her Stroke and Neurocritical Care fellowship at Brigham and Women's Hospital, taking on a faculty position at Harvard Medical School soon after in 2001. Dr. Sorond joined Northwestern in 2015 as a professor and the Vice Chair for Faculty Development for the Department of Neurology. In 2017, she was appointed the Division Chief for Stroke and Neurocritical Care. Two years later in 2019, she was named Associate Dean for Faculty Development at Feinberg School of Medicine. As of September 2022, Dr. Sorond is the Vice Dean for Faculty Affairs at Feinberg School of Medicine.

Dr. Sorond is a vascular neurologist focused on understanding, preventing, and treating vascular contributions to acute and chronic brain injury and age-related consequences of motor and cognitive decline. She has made multiple significant scientific discoveries that have advanced our understanding of brain vascular aging and cerebral small vessel function focused primarily on age-related brain white matter lesions (WML) and the accompanying decline in cognition and mobility. In search of compensatory mechanisms underpinning age-related resilience, she has identified enhanced neurovascular coupling in individuals who maintain mobility despite a large burden of WML.

As a clinician, Dr. Sorond has honed her skills in vascular cognitive neurology and care for patients that live at the margins of behavioral neurology clinics (focused on memory disorders prominent in AD) and stroke clinics (focused on acute stroke care and stroke prevention); all neglecting the slow loss of executive function and mobility, and subsequently independence, which are hallmarks of vascular cognitive impairment and eventually dementia. As a neurointensivist, she has directly observed the critical impact of brain resilience and vulnerability on an individual's potential for recovery from acute injury.

Larry & Karen Squiers

Larry was diagnosed with probable Lewy Body dementia in 2020, after a multi-year journey through the medical system and multiple diagnoses. He had a 30-year career in Fire Service, serving as Chief of his department for his last 10 years. After retirement, he and his wife of 43 years, Karen, traveled the country in their RV for 14 months until it became obvious that extended travel was no longer possible with the symptoms Larry was exhibiting.

Since his diagnosis, Larry has become a fierce advocate for change by working to break stigma and reshape conversations about dementia at community gatherings, donor events and research discussions. He has participated in support groups with others dealing with a dementia diagnosis, offering his solutions to various issues that arise. He served as a mentor for college students going into a medical field, to help acquaint them with dementia as a lived experience. His willingness to share his journey has left an impact on dementia awareness, research and support.

Larry's wife and care partner, Karen, worked in various areas of public service and ended her career as an elected official for their county. Her experiences in public speaking, serving as a Hospice volunteer and helping her own mother to cope with the challenges of aging were all components of her becoming a successful advocate not only for Larry, but for the greater dementia community. She has served on panels at dementia conferences, participated in research studies, spoken at donor events and provides support to other caregivers through various support groups.



M. Carmela Tartaglia, M.D., FRCPC

University of Toronto

Dr. Tartaglia is a Professor and Clinician-Scientist at the University of Toronto. She received her medical degree from McGill University, completed her residency at the University of Western Ontario and did three years of clinical/research fellowship in cognitive/behavioral neurology at the University of California, San Francisco Memory and Aging Center. She maintains a cognitive/behavioral clinic where she sees people with neurodegenerative disease and post-concussion syndrome within the UHN Memory Clinic. Her clinical and research interests lie in neurodegenerative diseases with a focus on frontotemporal lobar degeneration (FTLD) and possible chronic traumatic encephalopathy.

Angela Taylor
Lewy Body Dementia Association (LBDA)

Angela Taylor leads research and advocacy initiatives at the Lewy Body Dementia Association (LBDA), and works closely with LBDA's Research Centers of Excellence network. Bringing personal experiences as a former LBD caregiver for her father, she is regularly invited to speak to lay and professional audiences, as well as the media, on the impact of LBD. A nationally recognized LBD advocate, she served a 4-year term on the federal Advisory Council on Alzheimer's Research, Care and Services. She currently serves as co-chair of the Dementia Nomenclature Initiative Steering Committee, a national initiative to explore opportunities to improve communication about dementia and the diseases that cause it.

John-Paul Taylor, Ph.D.
Newcastle University, UK

Dr. John-Paul Taylor MBBS(hons) MRCPsych Ph.D. is an academic old age psychiatrist and Honorary Consultant at Newcastle University and Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust. Dr. John-Paul Taylor graduated with honors and distinction from the University of Newcastle upon Tyne having completed an intercalated M.D. Ph.D. programme in 2001. He subsequently worked in the Institute of Psychiatry at the Maudsley Hospital in London, before completing clinical academic training in Newcastle upon Tyne. In 2010 he was awarded a Wellcome Trust Clinical Scientist Fellowship and was appointed in 2019 as Professor of Translational Dementia Research at Newcastle University.

Dr. Taylor has received academic recognition for his work including being awarded a Foulkes Foundation Fellowship, the Sir James Spence Prize for best research, the Senta Travel Prize and Fellowship, the ICGP International Junior Investigator Award as well as being the recipient of the International Psychogeriatric Association Biennial Junior Research Award 1st Place.

Ranked in the top five experts internationally in Lewy body disease internationally (expertscape.com) Dr. Taylor's research focuses the application of neuroimaging and neurophysiological approaches in understanding symptom aetiology in dementia with Lewy bodies and Parkinson's disease dementia as well as developing better management approaches clinically for people with Lewy body disease. Clinically he leads a specialist Lewy body dementia clinic in Newcastle upon Tyne, United Kingdom.

Jacqueline M. Torres, Ph.D., MPH
University of California, San Francisco

Dr. Torres is a social epidemiologist and Assistant Professor in the Department of Epidemiology and Biostatistics at University of California, San Francisco. Dr. Torres' current research focuses on the role of policies, families, and community social networks in shaping population health and health inequities, particularly in mid and late-life. Her ongoing research is examining the role of family social connections, caregiving, and household composition changes in shaping late-life health, including Alzheimer's disease and related dementias. She approaches her research from a life-course perspective and social determinants of health framework. Much of her ongoing research employs modern epidemiologic methods that are better equipped than conventional methods at estimating the impact of time-varying exposures in the presence of time-varying confounding. Dr. Torres is also supporting trainees at all levels who are leading research broadly on the social determinants of inequity in health and aging and specifically related to policy impacts on the health of immigrants and their family and community members across the life-course.

Robert W. Turner II, Ph.D.
The George Washington University School of Medicine & Health Science

He earned his Ph.D. in sociology at the Graduate Center, City University of New York. He also holds a position as a Research Scientist in the Center on Health & Society at Duke University. After attending James Madison University on an athletic scholarship, Dr. Turner played football professionally in the now defunct United States Football League, the Canadian Football League, and briefly in the National Football League.

Keith Vossel, M.D.
University of California, Los Angeles

Dr. Keith Vossel is the Michael M. Minchin, Jr., President, J.D. French Alzheimer's Foundation Endowed Chair and Professor of Neurology in the David Geffen School of Medicine at UCLA. He received a master's degree in biomedical engineering and medical degree with highest honors from the University of Tennessee. He completed neurology residency at Harvard Medical School/Massachusetts General Hospital and Brigham and Women's Hospital, where he served as chief resident. Dr. Vossel completed fellowship training in behavioral neurology and dementia research at the University of California, San Francisco and Gladstone Institutes.

Dr. Vossel investigates Alzheimer's disease and related dementias with a focus on brain rhythm abnormalities and translational therapies. Key discoveries include the presence of silent epileptic activity, occurring during sleep and accelerating cognitive decline in Alzheimer's disease, effects of amyloid-β and tau deposition on brain rhythms and related cognitive impairments in Alzheimer's disease, and novel pathological functions of tau in Alzheimer's disease and dementia with Lewy bodies. Dr. Vossel led a phase 2a clinical trial showing that low doses of an antiseizure drug can improve memory and problem solving in patients with Alzheimer's disease and detectable epileptic activity. Dr. Vossel is broadening these studies in Greater Los Angeles and incorporating them into the expanded activities of Alzheimer's disease research.

Charles Windon, M.D.
University of California, San Francisco

Dr. Windon is an assistant professor of clinical neurology at the UCSF Memory and Aging Center. In this role, he participates in the clinical care of those with neurodegenerative disease and participates in the research evaluations of those referred to the Memory and Aging Center with a multitude of neurological conditions. He is also involved in the community outreach program at the MAC, with a particular interest in outreach to underserved communities, especially the African American community within the San Francisco Bay Area.

In his career, Dr. Windon seeks to further our understanding of neurodegenerative disease and the significance of biological markers of disease among underserved populations that have traditionally not been included in research, with the goal of providing better care and better opportunities for therapy. Charles received his Bachelor of Arts degree from Princeton University before obtaining his medical degree from Rutgers-Robert Wood

Johnson Medical School in New Jersey. He completed his residency training in neurology at the University of California, Los Angeles, and his Behavioral Neurology Fellowship at the UCSF Memory and Aging Center.

Charisse Winston, Ph.D.
University of Southern California, Keck School of Medicine

Dr. Winston is an Assistant Professor at the University of Southern California (USC) in the Keck School of Medicine. She joined the department of Physiology and Neuroscience in August 2023 after completing her post-doctoral training and MOSAIC K99 fellowship at the University of California, San Diego (UCSD).

Dr. Winston received her Bachelor's in Biochemistry from the University of Virginia, her Master's in Biochemistry, and her Ph.D. in Neuroscience from Georgetown University. Dr. Winston's lab focuses on advancing the field of biofluid-based extracellular vesicles as biomarkers for early diagnosis of Alzheimer's disease and other age-related dementias while addressing brain health inequities that exist amongst underserved patient groups.

Michael Wolf, Ph.D.
Northwestern University Feinberg School of Medicine

Dr. Michael Wolf is a Professor of Medicine and serves as both Associate Chair for Research for the Department of Medicine at the Feinberg School of Medicine, Northwestern University, and Associate Division Chief for General Internal Medicine & Geriatrics. He is a health services researcher and cognitive/behavioral scientist with expertise in adult learning and cognition, health literacy, patient education, medication safety and adherence, and practical applications of health and consumer technologies for chronic disease self-management.

According to the National Library of Medicine, Dr. Wolf is the prolific author of health literacy-related articles (200+); he has served on multiple national panels on health literacy, health disparities, and chronic disease management – including the proper use of and adherence to multi-drug regimens. He currently leads several NIH, AHRQ, foundation and industry-sponsored trials that test different ways to leverage electronic health records and mobile applications to promote health behaviors, particularly medication use.

Philip Wong, Ph.D.
Johns Hopkins University, School of Medicine

Dr. Philip Wong is a professor of pathology and neuroscience at the Johns Hopkins University School of Medicine. His research focuses on understanding the molecular mechanisms of neurodegenerative disorders, such as Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS) - frontotemporal dementia (FTD).

Dr. Wong's team takes a molecular/cellular approach, including transgenic, gene targeting, and RNAi strategies in mice, to develop models that facilitate their understanding of pathogenesis of AD and ALS-FTD as well as the identification and validation of novel targets for mechanism-based therapeutics.

He received his undergraduate degree in biochemistry and his Ph.D. in biochemistry and molecular biology from the University of Western Ontario in Canada. He completed a postdoctoral fellowship in cellular and molecular biology at the Johns Hopkins University School of Medicine in the Department of Biological Chemistry. Dr. Wong joined the Johns Hopkins faculty in 1994.

Dr. Wong is a member of the Society of Neuroscience and a member of the editorial board for *Molecular Neurodegeneration*. Dr. Wong's work has been recognized with the 2004 Zenith Fellow's Award from the Alzheimer's Association and the 2007 MetLife Foundation Award for Medical Research in AD.

Julie K. Wood, M.D., MPH, FAAFP
American Academy of Family Physicians (AAFP)

Julie K. Wood, M.D., MPH, FAAFP, serves as senior vice president of research, science, and health of the public. She joined the AAFP in 2013 as vice president for health of the public and interprofessional activities after a lengthy period of member service with the organization, including serving on its Board of Directors.

Dr. Wood oversees AAFP efforts to involve family physicians with integration of primary care and public health, health equity, population and community health, and global health. Science staff develop clinical policies and support, conduct, and disseminate practice-based primary care research with the aim of improving health and healthcare for patients, their families, and communities. As Senior Vice President, Dr. Wood also helps direct organization-wide strategy and policy-development activities in addition to actively participating in the work of the AAFP Board of Directors. She is based at AAFP's headquarters office in Leawood, Kans.

Prior to joining the AAFP staff, Dr. Wood was a practicing family physician for nearly 20 years, starting out as a solo rural family physician in her hometown of Macon, Mo. and then residency faculty at the Research Medical Center in Kansas City. Dr. Wood earned her undergraduate and medical degrees from the University of Missouri-Kansas City. She then completed her residency at Via Christi-St. Francis Family Medicine Residency Program in Wichita, Kans. She earned her master's degree in public health from the University of West Florida. She is board certified by the American Board of Family Medicine and has the AAFP Degree of Fellow, an earned degree awarded to family physicians for distinguished service and continuing medical education.

Andrew Yang, Ph.D.
University of California, San Francisco

Dr. Yang is an engineer-turned-neuroscientist developing new molecular approaches to decode the meaning, mechanisms, and therapeutic relevance of protein and immune crosstalk between the brain and body. He joined UCSF as a Sandler Faculty Fellow (2022) and recently started at the Gladstone Institutes & UCSF as an Assistant Professor. Dr. Yang obtained a Bachelor of Science in mechanical engineering and materials science at MIT and Ph.D. in bioengineering at Stanford.



Hyun-Sik Yang, M.D.
Brigham and Women's Hospital & Harvard Medical School

Dr. Yang is an Assistant Professor of Neurology at Harvard Medical School, an Associate Neurologist at Brigham and Women's Hospital, and an Associate Member (faculty) at the Broad Institute of MIT and Harvard. Dr. Yang is a physician scientist with clinical and scientific expertise in Alzheimer's disease and related neurocognitive disorders.

Dr. Yang graduated from Seoul National University College of Medicine (South Korea) and finished his residency at the Harvard Neurology Residency Program at Brigham and Women's Hospital and Massachusetts General Hospital (2016). He finished his behavioral neurology and neuropsychiatry fellowship at Brigham and Women's Hospital (2018).

Dr. Yang's research focuses on defining genetic and molecular underpinnings of LATE-NClimbic-predominant age-related TDP-43 encephalopathy neuropathological change), a recently recognized common neuropathology that is a key determinant of the clinical progression of Alzheimer's disease and Alzheimer's disease-related dementia. Dr. Yang's research program aims to translate advances in omics research to the clinical care of Alzheimer's disease and related late-onset neurocognitive disorders, by generating

comprehensive molecular data from human samples and analyzing them together with clinical and pathological data, using advanced computational approaches.

Paul A. Yushkevich, Ph.D.
University of Pennsylvania Perelman School of Medicine

Dr. Yushkevich is an Associate Professor in the Department of Radiology at the University of Pennsylvania and a member of the Bioengineering Graduate Group. His research focuses on developing novel computational methodologies for the analysis of biomedical imaging data. His graduate work, performed under the direction of Stephen M. Pizer, Ph.D. at the University of North Carolina, worked on the problems of finding shape representations suitable for statistical shape analysis with features derived from geometrical skeletons, and developed the continuous medial representation (cm-rep) approach. Dr. Yushkevich has continued this research in my postgraduate work, developing new ways to use differential equations to solve the complex geometrical constraints that arise in skeleton-based shape analysis, applying this methodology to the problems of shape analysis, shape-based normalization of brain structures, detailed structure-specific fMRI analysis, and tract-specific diffusion MRI analysis.

As part of this structure-specific framework, Dr. Yushkevich has developed a detailed atlas of the hippocampal region, derived from high-field, ultra high-resolution MRI images and dense histology stacks, along with techniques for leveraging this atlas in the analysis of in vivo MRI. His other work includes multi-atlas and shape-based segmentation algorithms, applied to problems in neuroimaging and cardiac imaging (including first-place finishes in segmentation grand challenges at MICCAI 2012 and MICCAI 2013), techniques for the analysis of functional and diffusion MRI data, groupwise registration, and many other image analysis topics. In addition to theoretical and applied image analysis research, Dr. Yushkevich is deeply involved in efforts to make complex image analysis tools available broadly in the form of software applications. He currently supervises the development of ITK-SNAP, a mature multi-platform, open-source image segmentation software tool that is used widely in the field, and the companion tool Convert3D.

Kristen Zuloaga, Ph.D.
Albany Medical College

Dr. Zuloaga joined the Department of Neuroscience & Experimental Therapeutics (DNET) at Albany Medical College in February 2017. She obtained her Ph.D. in Biomedical Sciences in 2011 and has been trained by leaders in the fields of neuroendocrinology (Dr. Robert Handa), cerebral vascular physiology and cerebral ischemia (Dr. Nabil Alkayed and Dr. Rayna Gonzales), aging and neurogenesis (MacArthur Fellow Dr. Sally Tempe).

She has served as both Council member and Education co-Chair for the Organization for the Study of Sex Differences and currently serves on the Editorial Board for *Biology of Sex Differences* and for *Alzheimer's & Dementia*, on the Scientific Advisory Board for the Albert Research Institute for White Matter and Cognition, the Scientific Advisory Board for Albany Medical College, and the External Advisory Board for the NIA CNS-Met COBRE. She is a standing member of the Chronic Dysfunction & Neurodegeneration (CDIN) study section for NIH.

Dr. Zuloaga is deeply committed to mentorship and is Co-Founder of the NY Capital Region Postdoctoral Development Program and Director of Graduate Studies in DNET. She has received funding at every stage of her career including her current NINDS R01 renewal, NIA U01, NIA R21, Alzheimer's Association AARG and AARG-D, and 11 other current or previous grants (NIH and multiple foundations).